WO2024251820A1 - Préparation de bibliothèques de liants bispécifiques exprimés dans des cellules eucaryotes - Google Patents

Préparation de bibliothèques de liants bispécifiques exprimés dans des cellules eucaryotes Download PDF

Info

Publication number
WO2024251820A1
WO2024251820A1 PCT/EP2024/065476 EP2024065476W WO2024251820A1 WO 2024251820 A1 WO2024251820 A1 WO 2024251820A1 EP 2024065476 W EP2024065476 W EP 2024065476W WO 2024251820 A1 WO2024251820 A1 WO 2024251820A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
bispecific
library
dna
binders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2024/065476
Other languages
English (en)
Inventor
Kothai Nachiar Devi PARTHIBAN
Peter SLAVNY
Cyril V. Privezentzev
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Iontas Ltd
Original Assignee
Iontas Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iontas Ltd filed Critical Iontas Ltd
Priority to EP24731906.4A priority Critical patent/EP4724577A1/fr
Priority to AU2024284377A priority patent/AU2024284377A1/en
Priority to CN202480045689.1A priority patent/CN121729490A/zh
Publication of WO2024251820A1 publication Critical patent/WO2024251820A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • C07K16/088—Varicella-zoster virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Definitions

  • aspects and embodiments described herein relate to the field of production of libraries of eukaryotic cell clones, specifically to libraries of eukaryotic cell clones containing DNA encoding a diverse repertoire of bispecific binders.
  • Bispecific antibodies have the potential to overcome these drawbacks, but their success has been hindered by the complexities associated with generating appropriate molecules for both research- and large-scale manufacturing purposes and by the lack of suitable libraries of bispecific antibodies for functional screening. Indeed: while over 100 different bispecific antibody formats have been described, a reliable approach for the generation of diverse, high-affinity antibody libraries has not been shown for most of them. One of the major hurdles is related to the difficulties associated with achieving successful expression of correctly formatted bispecific antibodies.
  • bispecific antibody format optimization is needed to have both bispecific modules selected to achieve the proper folding of both modules.
  • the expressed bispecific antibody must still be fully functional, i.e. able to simultaneously bind its two antigens.
  • the functional activity of bispecifics, particularly for bispecific antibodies that rely on the simultaneous binding to 2 different targets, is poorly predictable from that of the individual parental antibodies.
  • the methods described herein allow display of bi- and multispecific antibodies in the final desired (therapeutic) format using mammalian display avoiding the need to investigate all individual members of such a bispecific antibody.
  • WO2015/166272 describes a method of producing a library of eukaryotic cell clones containing DNA encoding a diverse repertoire of binders. WO2015/166272 does not relate specifically to bispecific antibodies and does not disclose a method for producing libraries of bispecific antibodies, especially not for bispecific antibodies comprising a first binding domain coupled to a first Fc domain and a second binding domain coupled to a second Fc domain.
  • bispecific antibodies particularly bispecific antibodies comprising a first binding domain coupled to a first Fc domain and a second binding domain coupled to a second Fc domain
  • bispecific antibodies can be successfully displayed while retaining their full functionality of binding to two separate antigens (i.e. , achieving proper expression and display on the cell surface, achieving proper folding of both binding domains, and avoiding steric hindrance or interference between both variable domains). Therefore, the methods disclosed herein make possible the construction of bispecific mammalian display libraries.
  • a method for producing a library of eukaryotic cell clones containing DNA encoding a diverse repertoire of bispecific binders comprising: providing eukaryotic cells; providing a plurality of donor DNA molecules, each donor DNA molecule comprising a first nucleic acid sequence encoding a first binding domain coupled to a first Fc domain; and a second nucleic acid sequence encoding a second binding domain coupled to a second Fc domain; introducing the donor DNA into the cells; and culturing the recombinant cells to produce clones, thereby providing a library of eukaryotic cell clones containing DNA encoding the repertoire of bispecific binders.
  • the first and second Fc domains are engineered to promote heterodimerization.
  • a method for producing a library of eukaryotic cell clones containing DNA encoding a diverse repertoire of bispecific binders comprising: providing eukaryotic cells; providing a plurality of donor DNA molecules, each donor DNA molecule comprising a first nucleic acid sequence encoding a first binding domain coupled to a first Fc domain; and a second nucleic acid sequence encoding a second binding domain coupled to a second Fc domain, wherein the first and second Fc domains are engineered to promote heterodimerization; introducing the donor DNA into the cells; and culturing the recombinant cells to produce clones, thereby providing a library of eukaryotic cell clones containing DNA encoding the repertoire of bispecific binders.
  • a method according to this aspect may be called “a method for producing a library as described herein” or “a method for producing a library” or the like in the context of this disclosure.
  • a method for producing a library as described herein is such that the first and/or second binding domain comprises a single antibody variable domain, preferably a variable domain derived from a heavy-chain antibody such as a VHH or a VNAR, and/or wherein the first and/or second binding domain comprises two antibody variable domains, preferably a single-chain variable fragment (scFv).
  • the first binding domain comprises a single antibody variable domain, preferably a variable domain derived from a heavy-chain antibody such as a VHH or a NAR, more preferably a VHH.
  • the second binding domain comprises two antibody variable domains, preferably a single-chain variable fragment (scFv).
  • a method for producing a library as described herein is such that the first and second Fc domain are engineered to promote heterodimerization, preferably wherein the first Fc domain comprises a knob mutation and the second Fc domain comprises a hole mutation, or wherein the first Fc domain comprises a hole mutation and the second Fc domain comprises a knob mutation.
  • Bispecific binders according to this disclosure are preferably multimeric binders comprising at least a first and second subunit (i.e. , separate polypeptide chains). More preferably, bispecific binders according to this disclosure are dimeric binders. Multimeric binders including dimeric binders may be obtained by expression and assembly of the
  • SUBSTITUTE SHEET (RULE 26) separately encoded subunits.
  • the multiple subunits may be encoded on the same molecule of donor DNA, as described above. However, it may also be desirable to integrate the different subunits into separate loci, in which case the subunits can be provided on separate donor DNA molecules. These could be integrated within the same step of introducing the donor DNA into the cells or they may be integrated sequentially.
  • methods for producing libraries of eukaryotic cell clones containing DNA encoding a diverse repertoire of multimeric, e.g. dimeric, bispecific binders may comprise: providing eukaryotic cells containing DNA encoding a first subunit of the bispecific binders, the DNA comprising a first nucleic acid sequence encoding a first binding domain coupled to a first Fc domain; providing a plurality of donor DNA molecules encoding a second subunit of the bispecific binders, each donor DNA molecule comprising a second nucleic acid sequence encoding a second binding domain coupled to a second Fc domain; introducing the donor DNA into the cells, thereby creating recombinant cells which contain donor DNA integrated in the cellular DNA; and culturing the recombinant cells to produce clones containing DNA encoding the first and second subunits, thereby providing a library of eukaryotic cell clones containing DNA encoding the repertoire of bispecific binders.
  • donor DNA encoding a second subunit is introduced into cells already containing DNA encoding a first subunit.
  • An alternative approach is to integrate a first subunit in a first cycle of introducing donor DNA, followed by introducing the second subunit in a second cycle of introducing donor DNA.
  • methods for producing libraries of eukaryotic cell clones containing DNA encoding a diverse repertoire of multimeric, e.g. dimeric, bispecific binders may comprise: providing eukaryotic cells; providing a plurality of first donor DNA molecules encoding a first subunit of the bispecific binders, each donor DNA molecule comprising a first nucleic acid sequence encoding a first binding domain coupled to a first Fc domain; introducing the first donor DNA into the cells to create a first set of recombinant cells containing the first donor DNA integrated in the cellular DNA; culturing the first set of recombinant cells to produce a first set of clones containing DNA encoding the first subunit;
  • SUBSTITUTE SHEET (RULE 26) providing a plurality of second donor DNA molecules encoding a second subunit of the bispecific binders, each donor DNA molecule comprising a second nucleic acid sequence encoding a second binding domain coupled to a second Fc domain; introducing the second donor DNA into cells of the first set of clones to create a second set of recombinant cells containing the first and second donor DNA integrated in the cellular DNA; and culturing the second set of recombinant cells to produce a second set of clones containing DNA encoding the first and second subunits, thereby providing a library of eukaryotic cell clones containing DNA encoding the repertoire of bispecific binders.
  • methods for producing libraries of eukaryotic cell clones containing DNA encoding a diverse repertoire of multimeric, e.g. dimeric, bispecific binders may comprise: providing eukaryotic cells; providing a plurality of first donor DNA molecules encoding a first subunit of the bispecific binders, each donor DNA molecule comprising a first nucleic acid sequence encoding a first binding domain coupled to a first Fc domain; providing a plurality of second donor DNA molecules encoding a second subunit of the bispecific binders, each donor DNA molecule comprising a second nucleic acid sequence encoding a second binding domain coupled to a second Fc domain; introducing the first and second donor DNA into the cells to create recombinant cells containing the first and second donor DNA integrated in the cellular DNA; and culturing the recombinant cells to produce clones, thereby providing a library of eukaryotic cell clones containing DNA encoding the repertoire of bispecific antibodies.
  • a method as described herein and similar expressions as used herein refer to any of the above methods for producing libraries of eukaryotic cell clones encoding a diverse repertoire of (multimeric, including dimeric) bispecific binders.
  • Methods as described herein such as methods for generating a library may involve providing a site-specific nuclease which cleaves a recognition sequence in cellular DNA. More particularly, in some embodiments in the context of methods as described herein,
  • the step of introducing donor DNA into cells comprises providing a site-specific nuclease within the cells, wherein the nuclease cleaves a recognition sequence in cellular DNA to create an integration site at which the donor DNA becomes integrated into the cellular DNA, integration occurring through DNA repair mechanisms endogenous to the cells, thereby creating recombinant cells containing donor DNA integrated in the cellular DNA.
  • the donor DNA molecules are flanked by homology arms. This may increase the integration efficiency.
  • the donor DNA molecules comprise a first promoter operably linked to the first nucleic acid sequence and/or the donor DNA molecules comprise a second promoter operably linked to the second nucleic acid sequence.
  • the donor DNA molecules comprise a bidirectional promoter operably linked to the first and second nucleic acid sequence. In some embodiments, the donor DNA molecules comprise a bidirectional promoter operably linked to the first and second nucleic acid sequence. In some embodiments, the first and/or second nucleic acid sequence encodes a membrane anchor, such as a transmembrane domain or a membrane localization signal. In some embodiments, the eukaryotic cells are higher eukaryotic cells with a genome size of greater than 2 x 10 7 base pairs, preferably mammalian, avian, insect or plant cells, more preferably mammalian cells.
  • a library of eukaryotic cell clones containing DNA encoding a diverse repertoire of bispecific binders wherein the library is obtained via a method for generating a library as described herein.
  • libraries according to this aspect may be called a “library as described herein” or the like in the context of this application.
  • Methods as described herein can generate libraries of eukaryotic cell clones that express a diverse repertoire of bispecific binders, each cell containing recombinant DNA
  • SUBSTITUTE SHEET (RULE 26) wherein donor DNA encoding a bispecific binder or subunit of a bispecific binder is integrated.
  • the donor DNA may be integrated at a fixed locus, or optionally at multiple fixed loci, in the cellular DNA.
  • fixed it is meant that the locus is the same between cells.
  • Cells used for creation of the library may therefore contain a nuclease recognition sequence at a fixed locus, representing a universal landing site in the cellular DNA at which the donor DNA can integrate.
  • the recognition sequence for the site-specific nuclease may be present at one or more than one position in the cellular DNA.
  • an in vitro library of eukaryotic cell clones that express a diverse repertoire of at least 10 A 3, 10 A 4, 10 A 5, 10 A 6, 10 A 7, 10 A 8 or 10 A 9 different bispecific binders, each cell containing recombinant DNA wherein donor DNA encoding a bispecific binder or subunit of a bispecific binder is integrated in at least a first and/or a second locus in the cellular DNA; optionally wherein the locus is a fixed locus.
  • a “library as described herein” or the like as used herein also refers to such an in vitro library of eukaryotic cell clones.
  • a library may be cultured to express the bispecific binders, thereby producing a diverse repertoire of bispecific binders.
  • a library may be used for screening for cells displaying a desired phenotype, wherein the phenotype results from expression of a bispecific binder by a cell.
  • a method of screening for a cell of a desired phenotype, wherein the phenotype results from expression of a bispecific binder by the cell comprising: providing a library via the method for producing a library as described herein, or providing a library as described herein; culturing the library cells to express the bispecific binders; and detecting whether the desired phenotype is exhibited.
  • a method according to this aspect may be called “a method of screening for a cell of a desired phenotype as described herein” or the like. “A method as described herein” and the like as used herein also refers to the above method of screening for a cell of a desired phenotype.
  • Phenotype screening is possible in which library cells are cultured to express the bispecific binders, followed by detecting whether the desired phenotype is exhibited in clones of the library.
  • Cellular read-outs can be based on alteration in cell behaviour such as altered expression of endogenous or exogenous reporter genes, differentiation status, proliferation, survival, cell size, metabolism or altered interactions with other cells.
  • cells of a clone that exhibits the desired phenotype may then be recovered.
  • DNA encoding the bispecific binder is
  • SUBSTITUTE SHEET (RULE 26) then isolated from the recovered clone, providing DNA encoding a bispecific binder which produces the desired phenotype when expressed in the cell.
  • the DNA encoding a bispecific binder which produces the desired phenotype may be sequenced.
  • a library may also be used for screening to identify bispecific binders that recognise a target of interest, optionally two targets of interest.
  • a method for screening to identify bispecific binders to a target of interest, optionally two targets of interest comprising: providing a library via the method for producing a library as described herein, or providing a library as described herein; culturing cells of the library to express the bispecific binders; exposing the bispecific binders to the target, optionally to the two targets, allowing recognition of the target, optionally of the two targets, by one or more binders of interest, if present; and detecting whether the target, optionally the two targets, is recognised by a binder of interest.
  • a method according to this aspect may be called “a method for screening to identify a binder to a target of interest as described herein” or “a method for screening to identify a binder” or the like. “A method as described herein” as used herein also refers to the above method for screening to identify a binder to a target of interest.
  • a library is cultured to express the bispecific binders, and the bispecific binders are exposed to the target(s) to allow recognition of the target(s) by one or more binders of interest, if present, and detecting whether the target(s) is recognised by a binder of interest.
  • cells of a clone containing DNA encoding the binder of interest may then be recovered.
  • DNA encoding the bispecific binder is then isolated from the recovered clone, providing DNA encoding a bispecific binder that binds the target(s) of interest.
  • the DNA encoding a binder that recognises the target may be sequenced.
  • bispecific binders may be displayed on the cell surface and those clones of the library that display bispecific binders with desired properties can be isolated.
  • cells incorporating genes encoding bispecific binders with desired functional or binding characteristics could be identified within the library.
  • the genes can be recovered and used for production of the bispecific binder or used for further engineering to create derivative libraries of bispecific binders to yield bispecific binders with improved properties.
  • a bispecific binder that has been identified from a library as described herein, for example a bispecific binder that was identified using a method for screening to identify a bispecific binder to a target of interest as described herein.
  • Preferred bispecific binders are described elsewhere herein.
  • a "binder” as described herein is a binding molecule, representing a specific binding partner for another molecule.
  • specific binding partners are antibody-antigen and receptor-ligand.
  • a (bispecific) binder as described herein is a (bispecific) antibody.
  • a “bispecific binder” as used herein denotes a molecule comprising binding domains for two different antigens or two different epitopes on the same antigen.
  • a bispecific binder is composed of two "monospecific" subunits which can be brought together (heterodimerized) in a bispecific format, hence forming a "bispecific binder". Accordingly, throughout this disclosure, references to a "bispecific binder” may be replaced with references to "subunits of a bispecific binder". The subunits are typically engineered to promote the formation of the bispecific I heterodimeric format, for example by using Fc domains engineered to promote heterodimerization. Libraries of cell clones encoding a repertoire of such bispecific binders allow the identification of optimal bispecific binders directly in the final (therapeutic) format.
  • the repertoire of bispecific binders encoded by a library will usually share a common structure (constant domain, e.g. Fc domain) and have one or more regions of diversity (variable domain).
  • the library therefore enables selection of a member of a desired structural class of molecules.
  • the bispecific binders may be polypeptides sharing a common structure (constant domain, e.g. Fc domain) and having one or more regions of amino acid sequence diversity (variable domain).
  • bispecific antibody molecules may be antibody molecules of a common structural class, e.g., scFv-Fc or VHH- Fc, differing in one or more regions of their sequence.
  • Antibody molecules typically have
  • SUBSTITUTE SHEET (RULE 26) sequence variability in their complementarity determining regions (CDRs), which are the regions primarily involved in antigen recognition.
  • CDRs complementarity determining regions
  • a repertoire of bispecific binders as described herein may be a repertoire of bispecific antibody molecules which differ in one or more CDRs, for example there may be sequence diversity in all CDRs, or in one or more particular CDRs such as the heavy chain CDR3 and/or light chain CDR3.
  • multimeric binders e.g. dimeric bispecific binders
  • one subunit may be kept constant while the other subunit may have one or more regions of amino acid sequence diversity as described above.
  • repertoires of bispecific binders differing with respect to one or more linkers.
  • Linkers are described elsewhere herein in more detail and include, for example, the linkers linking the VH and VL domains of scFvs and the linkers linking a binding domain to an Fc domain.
  • a repertoire of bispecific binders as described herein may be a repertoire of bispecific antibody molecules which have the same CDR or the same variable region, but which differ with respect to a linker sequence.
  • Using repertoires of bispecific binders differing in one or more linkers allows the optimization of molecules in their final desired (therapeutic) format with respect to linker length and/or sequence.
  • repertoires of bispecific binders comprising humanized and/or low immunogenicity variants of bispecific binders.
  • Using such repertoires of humanized/low immunogenicity variants of bispecific binders allows the optimization of humanized/low immunogenic molecules in their final desired (therapeutic) format.
  • Techniques for antibody humanization and reducing immunogenicity are known to the skilled person, as described for example in Safdari et al. Antibody humanization methods - a review and update. Biotechnol Genet Eng Rev. 2013;29:175-86; and Ministro et al. Therapeutic Antibody Engineering and Selection Strategies. Adv Biochem Eng Biotechnol. 2020;171 :55-86, both incorporated herein by reference.
  • donor DNA encoding the bispecific binder may be provided as one or more DNA molecules.
  • donor DNA integrates into the cellular DNA at multiple integration sites, e.g., the first subunit at one locus and the second subunit at a second locus.
  • both subunits of a multimeric, e.g. dimeric, bispecific binder may be encoded on the same molecule of donor DNA which integrates in the cellular DNA, optionally at a fixed locus.
  • a bispecific binder may be a bispecific antibody molecule or a bispecific non-antibody protein that comprises two or more antigen-binding sites.
  • An antigen binding site may be provided by means of arrangement of peptide loops on non-antibody protein scaffolds such as fibronectin or cytochrome B etc., or by randomising or mutating amino acid residues of a loop within a protein scaffold to confer binding to a desired target (Haan & Maggos. BioCentury 2004; 12(5):A1-A6; Koide et al. Journal of Molecular Biology 1998; 284:1141-1151 ; Nygren et al. Current Opinion in Structural Biology 1997; 7: 463-469).
  • Protein scaffolds for antibody mimics are disclosed in W00034784 in which proteins (antibody mimics) are described that include a fibronectin type III domain having at least one randomised loop.
  • a suitable scaffold into which to graft one or more peptide loops, e.g., a set of antibody VH CDR loops, may be provided by any domain member of the immunoglobulin gene superfamily.
  • the scaffold may be a human or nonhuman protein.
  • a bispecific binder may comprise other amino acids, e.g., forming a peptide or polypeptide, such as a folded domain, or to impart to the molecule another functional characteristic in addition to the ability to bind antigen.
  • a bispecific binder may carry a detectable label, or may be conjugated to a toxin or a targeting moiety or enzyme (e.g., via a peptidyl bond or linker).
  • a bispecific binder may comprise a catalytic site (e.g., in an enzyme domain) as well as an antigen binding site, wherein the antigen binding site binds to the antigen and thus targets the catalytic site to the antigen.
  • the catalytic site may inhibit biological function of the antigen, e.g., by cleavage.
  • Bispecific antibodies are preferred bispecific binders. Over 100 different bispecific antibody formats are known (Brinkmann & Kontermann. MAbs 2017; 9(2): 182-212). Bispecific antibodies, as used herein, have defined specificities and are artificial or recombinant molecules that are not found in nature. Preferably, a bispecific antibody as described herein is a dimeric bispecific antibody, i.e. consisting of two separate polypeptide chains or "subunits".
  • preferred bispecific antibodies as described herein comprise a first binding domain coupled to a first Fc domain and a second binding domain coupled to a second Fc domain.
  • a binding domain may be coupled to an Fc domain either directly or indirectly, i.e. , by using a "linker” or “linker peptide". Particularly in the context of VHH binding domains (described in detail elsewhere herein), the binding domain may be coupled to the Fc domain through a linker.
  • linker a linker coupling a binding domain to an Fc domain is a flexible linker.
  • flexible linkers are generally composed of small, non-polar (e.g., glycine) or polar (e.g., serine and threonine) amino acids, allowing them to provide flexibility and mobility of the connecting functional domains (as reviewed in Chen et al., Adv Drug Deliv Rev 2013; 65(10): 1357-1369; Chichili et al. Protein Sci. 2013;22(2): 153-67, both incorporated herein by reference).
  • suitable flexible linkers include (GGGGS)n (SEQ ID NO: 25), wherein “n” is the number of repeats which may optionally be 2-7, preferably 3- 6.
  • a bispecific antibody comprising one binding site for each antigen may be denoted as a bivalent antibody.
  • the preferred bispecific antibodies of this disclosure comprising a first binding domain coupled to a first Fc domain and a second binding domain coupled to a second Fc domain may be denoted as bivalent bispecific antibodies.
  • Such bivalent bispecific antibodies may be described as having a “1+1” stoichiometry.
  • this disclosure also encompasses multivalent bispecific antibodies.
  • adding an additional binding domain to each of the polypeptide chains of a bivalent bispecific antibody as described herein results in tetravalent molecules with a “2 + 2” stoichiometry.
  • Other formats allow to generate “1 + 2” or “1 + 3” molecules, having one binding site for one antigen and 2 or 3 binding sites for the other antigen, respectively.
  • a bispecific antibody as described herein comprises:
  • binding domains coupled to a second Fc domain.
  • Bispecific antibodies as used herein may have either a symmetric or an asymmetric architecture, preferably an asymmetric architecture.
  • Bispecific antibodies having a symmetric architecture may be understood to be such that the binding domains coupled to the first Fc domain and the binding domains coupled to the second Fc domain are of the same type, while bispecific antibodies having an asymmetric architecture may be understood to be such that the binding domains coupled to the first Fc domain and the binding domains coupled to the second Fc domain are of a different type.
  • bispecific antibodies having a symmetric architecture may be understood to have a first and second binding domain of the same type, while bispecific antibodies having an asymmetric architecture may be understood to have a first and second binding domain of a different type. Suitable types of binding domains in the context of this disclosure are described below.
  • a binding domain may be any antibody or antibody fragment or antibody domain or the like capable of binding an antigen.
  • a binding domain, as used herein, may thus alternatively be referred to as an antigen-binding domain.
  • variable domains of both the light (VL) and heavy (VH) chain portions determine antigen recognition and specificity.
  • the constant domains of the light chain (CL) and the heavy chain (CH 1 , CH2 or CH3) confer other biological properties such as secretion, transplacental mobility, Fc receptor binding, complement binding, and the like.
  • the N- terminal portion is a variable region and at the C-terminal portion is a constant region; the CH3 and CL domains actually comprise the carboxy-terminus of the heavy and light chains, respectively.
  • VHHs In addition to conventional antibodies, made of two heavy and two light chains, certain vertebrates, notably Camelidae including dromedaries, camels, llamas, and alpacas; as well as some cartilaginous fishes such as sharks, produce so called heavy-chain antibodies that are antibodies made only of two heavy chains and lacking the two light chains present in conventional antibodies. In Camelidae, these are designated as VHHs
  • SUBSTITUTE SHEET (RULE 26) for variable domain of heavy-chain antibodies and in some cartilaginous fishes such as sharks, these are designated as VNARs for variable new antigen receptor.
  • binding domains in this disclosure are single-chain binding domains, i.e. the binding domains are monomeric.
  • a binding domain comprises at least one antibody variable domain. In some embodiments, the first and/or second binding domain comprises at least one antibody variable domain.
  • a binding domain comprises a single antibody variable domain.
  • the first and/or second binding domain comprises a single antibody variable domain.
  • Binding domains comprising a single antibody variable domain may also be denoted as single domain antibodies (sdAb).
  • An sdAb is a small monomeric antigen-binding fragment of an antibody, namely the variable region of an antibody heavy or light chain.
  • Heavy-chain antibodies found in Camelidae are composed of two heavy chains divided in three domains each: CH3-CH2-VHH.
  • the variable domain of HCAb corresponding to the paratope recognizing the antigen is called VHH. This variable domain can be expressed on its own and still recognize the antigen.
  • the amino acid sequence and structure of a VHH can be considered, without however being limited thereto, to be comprised of four framework regions or ‘FR's’, which are referred to in the art and herein below as ‘framework region T or ‘FRT; as ‘framework region 2’ or ‘FR2’; as ‘framework region 3’ or ‘FR3’; and as ‘framework region 4’ or ‘FR4’, respectively, which framework regions are interrupted by three complementary determining regions or ‘CDR's’, which are referred to in the art as ‘complementarity determining region T or ‘CDRT; as ‘complementarity determining region 2’ or ‘CDR2’; and as ‘complementarity determining region 3’ or ‘CDR3’, respectively.
  • FR's framework regions or ‘FR's’, which are referred to in the art and herein below as ‘framework region T or ‘FRT; as ‘framework region 2’ or ‘FR2’; as ‘framework region 3’ or ‘FR3’; and as ‘framework region 4
  • Heavy-chain antibodies found in sharks are composed of two heavy chains made of five constant domains (CNAR1 , CNAR2, CNAR3, CNAR4 and CNAR5).
  • VNARs are the variable domain of these antibodies.
  • VHHs VNARs bear full antigen recognition properties.
  • the main difference of their variable domain is the absence of complementary-determining region 2 (CDR2) leading to only two CDRs.
  • CDR2 complementary-determining region 2
  • a binding domain comprising a single antibody variable domain may be (i) a variable domain of the heavy chain of a heavy chain antibody, which is
  • SUBSTITUTE SHEET naturally devoid of light chains, including but not limited to the variable domain of the heavy chain of heavy-chain antibodies of camelids (VHH) or sharks (VNAR) or (ii) the variable domain of the heavy chain of a conventional four-chain antibody, including but not limited to a camelized variable domain of the heavy chain of a conventional four- chain.
  • a binding domain comprising a single antibody variable domain is a VHH or a VNAR, preferably a VHH.
  • a binding domain comprises two antibody variable domains.
  • the first and/or second binding domain comprises two antibody variable domains.
  • Binding domains comprising two single antibody variable domains are preferably single-chain variable fragments (scFv).
  • scFv molecules consist of a VH domain and a VL domain joined by a linker or linker peptide.
  • a linker coupling a VH domain and a VL domain is a flexible linker. Suitable flexible linkers are described herein elsewhere.
  • the VH and VL domains form a VH-VL pair in which the complementarity determining regions of the VH and VL come together to form an antigen binding site.
  • the 1 , 2, 3 or 4 binding domains coupled to a first Fc domain comprise a single antibody variable domain as described herein. In some embodiments, the 1 , 2, 3 or 4 binding domains coupled to a second Fc domain comprises two antibody variable domains as described herein. In some embodiments, the 1 , 2, 3 or 4 binding domains coupled to a first Fc domain comprise a single antibody variable domain as described herein, and the 1 , 2, 3 or 4 binding domains coupled to a second Fc domain comprise two antibody variable domains as described herein, or vice versa.
  • the first binding domain comprises a single antibody variable domain as described herein.
  • the second binding domain comprises two antibody variable domains as described herein.
  • the first and second binding domain are of a different type. Accordingly, in preferred embodiments, the first binding domain comprises a single antibody variable domain as described herein (e.g. a VHH), and the second binding domain comprises two antibody variable domains as described herein (e.g. an scFv), or vice versa.
  • bispecific antibodies described herein may comprise:
  • binding domains coupled to a second Fc domain.
  • bispecific antibodies as described herein comprise a first binding domain coupled to a first Fc domain and a second binding domain coupled to a second Fc domain.
  • Fc region, Fc domain and the like may be used interchangeably herein, and refer to the CH2 and CH3 domains of a canonical IgG antibody molecule.
  • the CH2 and CH3 domains are responsible for the interactions with effector cells and complement components within the immune system.
  • bispecific antibodies comprising an Fc domain have the advantage that they may display Fc-mediated effector functions, such as antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement fixation, and FcRn- mediated recycling.
  • ADCC antibody-dependent cell-mediated cytotoxicity
  • ADCP antibody-dependent cellular phagocytosis
  • complement fixation and FcRn- mediated recycling.
  • the Fc domains are engineered to promote heterodimerization.
  • the first and second Fc domain as described herein are different from each other.
  • the first and second Fc domain as described herein are different from each other and are engineered to promote heterodimerization.
  • the CH3 domain of the first Fc domain and the CH3 domain of the second Fc domain have corresponding mutations that promote dimerization.
  • Such mutations may for example be selected from the table below.
  • the knob-into-hole technique is based on creating a knob at the CH3 domain interface of the first chain by replacing one or more smaller amino acid side chains with larger ones (for example, T366Y or T366W or S354C+T366W); and creating a hole in the juxtaposed position at the CH3 interface of the second chain by replacing one or more larger amino acid side chains with smaller ones (for example, Y407T or T366S+L368A+Y407V or Y349C+T366S+L368A+Y407V). Because knob-knob and hole-hole interactions are sterically hindered or energetically less favorable, heterodimer formation is favored.
  • the first and second Fc domain in particular the CH3 region of the first and second Fc domains, comprises corresponding knob and hole mutations.
  • the first Fc domain may comprise a knob mutation and the second Fc domain may comprise a hole mutation, or the first Fc domain may comprise a hole mutation and the second Fc domain may comprise a knob mutation.
  • a knob mutation may be selected from the group consisting of: T366Y, T366W, and S354C+T366W.
  • a hole mutation may be selected from the group consisting of: Y407T, T366S+L368A+Y407V, and Y349C+T366S+L368A+Y407V.
  • Corresponding knob and hole mutations may be selected from the group consisting of:
  • an Fc domain comprising a knob mutation is coupled with a binding domain comprising a single antibody variable domain as described herein (e.g. a VHH) and/or an Fc domain comprising a hole mutation is coupled with a binding domain comprising two antibody variable domains as described herein (e.g. an scFv).
  • an Fc domain comprising a knob mutation is coupled with a VHH) and an Fc domain comprising a hole mutation is coupled with an scFv.
  • Bispecific binders may be (derived from) human antibody molecules. Thus, where constant domains are present these are preferably human constant domains.
  • SUBSTITUTE SHEET (RULE 26) A library as described herein may be used to select a bispecific antibody molecule that binds one or more antigens of interest. Selection from libraries is described in detail below.
  • the selected bispecific antibody molecules as well as their encoding nucleic acids and the sequences thereof are an aspect of the present disclosure.
  • Antibody molecules and their encoding nucleic acid may be provided in isolated form, or as cell clones containing said nucleic acid and expressing said molecules.
  • Bispecific antibody molecules may be selected from a library and then modified, for example the in vivo half-life of an antibody molecule can be increased by chemical modification, for example PEGylation, or by incorporation in a liposome.
  • VH and VL genes could be amplified from the B cells of immunised animals and cloned into an appropriate vector for introduction into eukaryotic libraries as described herein.
  • Phage display and ribosome display allows very large libraries (>10 A 9 clones) to be constructed enabling isolation of human antibodies without immunisation.
  • Producing libraries according to the present disclosure could also be used in conjunction with such methods.
  • the selected population of binders could be introduced into eukaryotic cells by nuclease-directed integration as described herein. This would allow the initial use of very large libraries based in other systems (e.g., phage display) to enrich a population of binders while allowing their efficient screening using eukaryotic cells as described above.
  • the disclosure can combine the best features of both phage display and eukaryotic display to give a high throughput system with quantitative screening and sorting.
  • binders without resorting to immunisation, provided display libraries of sufficient size are used. For example multiple binders were generated from a non-immune antibody library of >10 A 7 clones (Marks et al. J Mol Biol 1991 ; 222(3), 581-597). This in turn allows generation of binders to targets which are difficult by traditional immunisation routes e.g., generation of antibodies to “self-antigens” or epitopes which are conserved between species.
  • human/mouse cross- reactive binders can be enriched by sequential selection on human and then mouse versions of the same target. Since it is not possible to specifically immunise humans to most targets of interest, this facility is particularly important in allowing the generation of human antibodies which are preferred for therapeutic approaches.
  • SUBSTITUTE SHEET (RULE 26) binders, e.g., from immunisation or from engineering of pre-existing binders.
  • binders e.g., from immunisation or from engineering of pre-existing binders.
  • the ability to make large libraries in eukaryotic cells and particularly higher eukaryotes creates the possibility of isolating binders direct from these libraries starting with non-immune binders or binders which have not previously been selected within another system.
  • By producing a library according to the present disclosure it is possible to generate binders from non-immune sources. This in turn opens up the possibilities for using binder genes from multiple sources. Binder genes could come from PCR of natural sources such as antibody genes.
  • Binder genes could also be re-cloned from existing libraries, such as antibody phage display libraries, and cloned into a suitable donor vector for nuclease- directed integration into target cells. Binders may be completely or partially synthetic in origin. Furthermore various types of binders are described elsewhere herein, for example binder genes could encode antibodies or could encode alternative scaffolds (Skerra. Curr Opin Biotechnol 2007;18(4):295-304; Gebauer & Skerra. Curr Opin Chem Biol 2009; 13(3): 245-255), peptides or engineered proteins or protein domains.
  • Preferred eukaryotic cells and eukaryotic cell clones for aspects of this disclosure including the methods, uses and libraries as described herein are defined below. It is understood that all preferences relating to eukaryotic cells may also be applied to eukaryotic cell clones.
  • Eukaryotic cells are preferably higher eukaryotic cells, defined here as cells with a genome greater than that of Saccharomyces cerevisiae which has a genome size of 12 x 10 A 6 base pairs (bp).
  • the higher eukaryotic cells may for example have a genome size of greater than 2 x 10 A 7 base pairs.
  • the eukaryotic cells are higher eukaryotic cells with a genome size of greater than 2 x 10 A 7 base pairs.
  • eukaryotic cells are mammalian cells, e.g., mouse or human. More preferably, eukaryotic cells are human cells.
  • the eukaryotic cells may be primary cells or may be cell lines.
  • Chinese hamster ovary (CHO) cells are commonly used for antibody and protein expression but any alternative stable cell line such as HEK293 cells may be used in the disclosure.
  • Methods are available for efficient introduction of foreign DNA into primary cells allowing these to be used (e.g., by electroporation where efficiencies and viabilities up to 95 % have been achieved, Parthiban et al. MAbs 2019; 11 (5); 884-898; Dyson et al. MAbs 2020; 12(1):1829335).
  • a particular benefit of nuclease-directed integration comprised in a method for generating a library relates to integration of binder genes into higher eukaryotic cells with larger genomes where homologous recombination in the absence of nuclease
  • SUBSTITUTE SHEET (RULE 26) cleavage is less effective.
  • Yeast e.g., Saccharomyces cerevisiae
  • homologous recombination directed by homology arms in the absence of nuclease- directed cleavage
  • Nuclease-directed integration has been used in yeast cells to solve the problem of efficient integration of multiple genes into individual yeast cells, e.g., for engineering of metabolic pathways (US2012/0277120), but this work does not incorporate introduction of libraries of binders nor does it address the problems of library construction in higher eukaryotes.
  • Preferred eukaryotic cells are T lymphocyte lineage cells (e.g., primary T cells or a T cell line) or B lymphocyte lineage cells.
  • T lymphocyte lineage cells e.g., primary T cells or a T cell line
  • B lymphocyte lineage cells are primary T-cells or T cell derived cell lines for use in TOR libraries including cell lines which lack TOR expression (Letourneur, F., Malissen, B. European Journal of Immunology 1989; 19(12):2269 — 2274; Kanayama et al. Biochem Biophys Res Commun 2005; 327(1), 70 — 75; Lin et al. Nucleic Acids Research 2011 ; 39(3), e14.
  • Preferred B lymphocyte lineage cells are B cells, pre-B cells or pro-B cells and cell lines derived from any of these.
  • Repertoires of binders could be targeted to specific loci using zinc finger nucleases (ZFNs), TALE nucleases or CRISPR/Cas9 targeted to endogenous sequences or by targeting pre-integrated heterologous sites which could include meganuclease recognition sites.
  • ZFNs zinc finger nucleases
  • TALE nucleases or CRISPR/Cas9 targeted to endogenous sequences or by targeting pre-integrated heterologous sites which could include meganuclease recognition sites.
  • DT40 cells express antibodies and so it will be advantageous to target antibody genes within the antibody locus either with or without disruption of the endogenous chicken antibody variable domains.
  • DT40 cells have also been used as the basis of an in vitro system for generation of chicken IgMs termed the Autonomously Diversifying Library system (ADLib system) which takes advantage of intrinsic diversification occurring at the chicken antibody locus. As a result of this endogenous diversification it is possible to generate novel specificities.
  • nuclease-directed approach described here could be used in combination with ADLib to combine diverse libraries of binders from heterologous sources (e.g., human antibody variable region repertoires or synthetically derived alternative scaffolds) with the potential for further diversification with the chicken IgG locus. Similar benefits could apply to human B cell lines such as Nalm6 (Adachi et al. DNA and Cell Biology 2006; 25(1), 19-24).
  • SUBSTITUTE SHEET (RULE 26)
  • Other preferred B lineage cell lines preferred in methods for identifying a locus and for producing a library include lines such as the murine pre-B cell line 1624-5 and the pro- B cell line Ba/F3.
  • Ba/F3 is dependent on IL-3 (Palacios et al. Cell 1985;41(3), 727 — 734) and its use is discussed elsewhere herein.
  • the eukaryotic cells are preferably of a single type of cells, produced by introduction of donor DNA into a population of clonal eukaryotic cells, for example by introduction of donor DNA into cells of a particular cell line.
  • the main significant difference between the different library clones will then be due to integration of the donor DNA.
  • each cell will encode a binder capable of being incorporated into a viral particle.
  • the encoding mRNA would be packaged and the encoded binder would be presented on the cell surface.
  • genes encoding the binder would need to be encapsulated into the baculoviral particle to maintain an association between the gene and the encoded protein. This could be achieved using host cells carrying episomal copies of the baculoviral genome. Alternatively integrated copies could be liberated following the action of a specific nuclease (distinct from the one used to drive site-specific integration).
  • some partners could be encoded within the cellular DNA with the genes for one or more partners being packaged within the virus.
  • Methods described herein comprise the introduction of nucleic acids into a eukaryotic cell.
  • donor DNA molecules are introduced. Unless
  • the introduction of a nucleic acid refers to the introduction of a DNA molecule in a eukaryotic cell.
  • combinatorial libraries could be created wherein members of multimeric binding pairs (e.g., a first and a second subunit as described herein) or even different parts of the same binder molecule are introduced on different plasmids.
  • Introduction of separate donor DNA molecules encoding separate binders or binder subunits may be done simultaneously or sequentially.
  • a first subunit of a multimeric bispecific binder could be introduced by transfection or infection, the cells grown up and selected if necessary.
  • Other components, such as a second subunit of a multimeric bispecific binder could then be introduced in a subsequent infection or transfection step.
  • One or both steps could involve nuclease-directed integration to specific genomic loci.
  • a method for generating a library as described herein may involve the integration of nucleic acids into the genome of the eukaryotic cell.
  • genome and cellular DNA may be used interchangeably.
  • integration refers to the integration of a DNA molecule into the genome of a eukaryotic cell.
  • the nucleic acid is integrated into the genome (i.e. cellular DNA), forming recombinant DNA having a contiguous DNA sequence in which the nucleic acid is inserted at the integration site.
  • integration is mediated by the natural DNA repair mechanisms that are endogenous to the cell.
  • Integration of a nucleic acid may be random or specific.
  • the integration site is not defined by a specific sequence.
  • SUBSTITUTE SHEET (RULE 26) In specific integration of a nucleic acid the integration site is defined by a specific sequence.
  • the nucleic acid in the context of specific integration may be called the donor DNA, the donor DNA molecule or the donor DNA sequence or the like.
  • Specific integration can be allowed to occur by introducing the nucleic acid into a cell, allowing the site-specific nuclease to create an integration site, and allowing the donor DNA to be integrated.
  • specific integration may also be called nuclease- directed integration.
  • Cells may be kept in culture for sufficient time for the DNA to be integrated. This will usually result in a mixed population of cells, including (i) recombinant cells into which the donor DNA has integrated at the integration site created by the site-specific nuclease, and optionally (ii) cells in which donor DNA has integrated at sites other than the desired integration site and/or optionally (iii) cells into which donor DNA has not integrated.
  • the desired recombinant cells and the resulting clones may thus be provided in a mixed population further comprising other eukaryotic cells. Selection methods described elsewhere herein may be used to select the desired cells and clones, or to enrich said mixed population in said desired cells and clones.
  • Endogenous DNA repair mechanisms in eukaryotic cells include homologous recombination, non-homologous end joining (NHEJ) and microhomology-mediated end joining (MMEJ).
  • NHEJ non-homologous end joining
  • MMEJ microhomology-mediated end joining
  • the efficiency of integration by such processes can be increased by the introduction of double stranded breaks (DSBs) in the cellular DNA and efficiency gains of 40,000 fold have been reported using rare cutting endonucleases (meganucleases) such as l-Scel (Porteus & Baltimore. Science 2003; 300(5620): 763; Rouet et al. Molecular and Cellular Biology 1994; 14(12):8096- 8106; Jasin. Trends in genetics 1996; 12(6):224-228).
  • a method for generating a library preferably do not include a step of recombinase-mediated integration of a DNA molecule.
  • the eukaryotic cells in a method for identifying a locus and in a method for generating a library preferably lack a recombination site for a site-specific recombinase.
  • nuclease act to create breaks or nicks within the cellular DNA, which are exposed to and repaired by endogenous cellular repair mechanisms such as homologous recombination or NHEJ.
  • endogenous cellular repair mechanisms such as homologous recombination or NHEJ.
  • Recombinase-based approaches have an absolute
  • SUBSTITUTE SHEET (RULE 26) requirement for pre-integration of their recognition sites, so such methods require engineering of the “hot spot” integration site into the cellular DNA as a preliminary step.
  • nuclease-directed integration it is possible to engineer nucleases or direct via guide RNA in the case of CRISPR:Cas9 to recognise endogenous recognition sequences, i.e. , nucleic acid sequences occurring naturally in the cellular DNA.
  • nuclease-directed approaches are more efficient for specific integration of transgenes at the levels required to make large libraries of binders.
  • the DNA repair mechanism by which the donor DNA is integrated in a method as described herein such as a method for generating a library can be pre-determined or biased to some extent by design of the donor DNA and/or choice of site-specific nuclease.
  • Homologous recombination is a natural mechanism used by cells to repair double stranded breaks using homologous sequence (e.g., from another allele) as a template for repair.
  • homologous recombination has been utilised in cellular engineering to introduce insertions (including transgenes), deletions and point mutations into the genome.
  • Homologous recombination is promoted by providing homology arms on the donor DNA.
  • the donor DNA preferably comprises homology arms.
  • the original approach to engineering higher eukaryotic cells typically used homology arms of 5-10 kb within a donor plasmid to increase efficiency of targeted integration into the site of interest.
  • Homologous recombination is particularly suitable for eukaryotes such as yeast, which has a genome size of only 12.5 x 10 A 6 bp, where it is more effective compared with higher eukaryotes with larger genomes e.g., mammalian cells with 3000 x 10 A 6 bp.
  • Homologous recombination can also be directed through (Fujioka et al. Nucleic Acids Res 1993; 21(3): 407-412) nicks in cellular DNA and this could also serve as a route for nuclease-directed integration into cellular DNA.
  • the integration of donor DNA comprised in a method as described herein such as a method for generating a library preferably comprises the introduction of nicks in the cellular DNA. Two distinct pathways have been shown to promote homologous recombination at nicked DNA.
  • Non-homologous end-joining is an alternative mechanism to repair double stranded breaks in the genome where the ends of DNA are directly re-ligated without the need for a homologous template. Nuclease-directed cleavage of genomic DNA can also enhance transgene integration via non-homology based mechanisms. NHEJ provides a simple means of integrating in-frame exons into intron or allows integration
  • SUBSTITUTE SHEET (RULE 26) of promotergene cassettes into the genome.
  • Use of non-homologous methods allows the use of donor vectors which lack homology arms thereby simplifying the construction of donor DNA.
  • MMEJ microhomology-mediated end joining
  • a method for generating a library may involve providing a site-specific nuclease which cleaves a recognition sequence in cellular DNA.
  • site-specific nucleases are defined below. It is understood that all preferences relating to site-specific nuclease may also be applied mutatis mutandis to the corresponding recognition sites.
  • the site-specific nuclease cleaves cellular DNA following specific binding to a recognition sequence, thereby creating an integration site for donor DNA.
  • site, target site, recognition site and recognition sequence may be used interchangeably.
  • the nuclease may create a double strand break or a single strand break (a nick). Nuclease-mediated DNA cleavage enhances site-specific integration of binder genes through endogenous cellular DNA repair mechanisms.
  • the eukaryotic cells used may contain endogenous sequences recognized by the sitespecific nuclease or the recognition sequence may be engineered into the cellular DNA.
  • the site-specific nuclease may be exogenous to the cells, i.e. not occurring naturally in cells of the chosen type.
  • the sitespecific nuclease can be introduced before, after or simultaneously with introduction of the donor DNA. It may be convenient for the donor DNA to encode the nuclease in addition to a binder, or on separate nucleic acid which is co-transfected or otherwise introduced at the same time as the donor DNA. Clones of a library may optionally retain nucleic acid encoding the site-specific nuclease, or such nucleic acid may be only transiently transfected into the cells.
  • Any suitable site-specific nuclease may be used within this disclosure. It may be a naturally occurring enzyme or an engineered variant. There are a number of known nucleases that are especially suitable, such as those which recognise, or can be engineered to recognise, sequences that occur only rarely in cellular DNA.
  • the site-specific nuclease recognizes only one or two distinct recognition sequences. This is advantageous since this should ensure that only one or two molecules of donor DNA are integrated per cell.
  • the recognition sequence has a length of at least 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides.
  • the recognition sequence has a length from 10 up to 40, 39, 38, 37, 36, 35, 34, 33, 32, 31 , 30, 29, 28, 27, 26, 25, 24, 23, 22, 21 or 20 nucleotides, or from 12 up to 40, 39, 38, 37, 36, 35, 34, 33, 32, 31 , 30, 29, 28, 27, 26, 25, 24, 23, 22, 21 or 20 nucleotides.
  • Preferred site-specific nucleases are meganucleases, zinc finger nucleases (ZFNs), TALE nucleases, and nucleic acid-guided (e.g., RNA-guided) nucleases such as the CRISPR/Cas system. Each of these produces double strand breaks although engineered forms are known which generate single strand breaks.
  • Meganucleases are nucleases which occur across all the kingdoms of life and recognise relatively long sequences (12-40 bp). Given the long recognition sequence they are either absent or occur relatively infrequently in eukaryotic genomes. Meganucleases are grouped into 5 families based on sequence/structure. (LAGLIDADG (SEQ ID NO: 2) family, GIY-YIG family, HNH family, His-Cys box family and PD-(D/E)XK family). The best studied family is the LAGLIDADG (SEQ ID NO: 2) family which includes the well characterised l-Scel meganuclease from Saccharomyces cerevisiae.
  • I-Scel recognises and cleaves an 18 bp recognition sequence (5’ TAGGGATAACAGGGTAAT, SEQ ID NO: 1) leaving a 4 bp 3’ overhang.
  • Another commonly used example is l-Crel which originates from the chloroplast of the unicellular green algae of Chlamydomonas reinhardtii, and recognizes a 22 bp sequence (Silva et al. Current Gene Therapy 2011 ; 11 (1): 11-27).
  • a number of engineered variants have been created with altered recognition sequences (Epinat et al. Topics in Current Genetics 2013; 23: 147-185).
  • Meganucleases represent the first example of the use of site-specific nucleases in genome engineering [Rouet et al.
  • a preferred class of meganucleases is the LAGLIDADG (SEQ ID NO: 2) endonucleases. These include l-Scel, l-Chul, l-Cre I, Csml, Pl-Scel, Pl-Tlil, Pl-Mtul, l-Ceul, l-Scell, I- Scelll, HO, Pi-Civl, Pl-Ctrl, Pl-Aael, Pl-Bsul, Pl-Dhal, Pl-Dral, Pl-Mavl, Pl-Mchl, Pl-Mfu, Pl-Mfll, Pl-Mgal, Pl-Mgol, PI-Minl, Pl-Mkal, Pl-Mlel, Pl-Mrnal, Pl-Mshl, Pl-Msml, Pl- Mthl, Pl-Mtu, Pl-Mxel, Pl-Npul, Pl-Pful, Pl-Rmal, Pl-Spb
  • binding specificity can be directed by engineered binding domains such as zinc finger domains. These are small modular domains, stabilized by zinc ions, which are involved in molecular recognition and are used in nature to recognize DNA sequences.
  • Arrays of zinc finger domains have been engineered for sequence specific binding and have been linked to the non-specific DNA cleavage domain of the type II restriction enzyme Fok1 to create zinc finger nucleases (ZFNs). Such ZFNs are preferred site-specific nucleases herein.
  • ZFNs can be used to create double stranded break at specific sites within the genome.
  • Fok1 is an obligate dimer and requires two ZFNs to bind in close proximity to effect cleavage.
  • the specificity of engineered nucleases has been enhanced and their toxicity reduced by creating two different Fok1 variants which are engineering to only form heterodimers with each other [Doyon et al. Nat Methods 2011 ; 8(1): 74-79],
  • Such obligate heterodimer ZFNs have been shown to achieve homology-directed integration in 5-18 % of target cells without the need for drug selection (Moehle et al. PNAS 2007; 104(9): 3055-3060, Perez-Pinera et al.
  • TALE Transcription activator-like effectors
  • CRISPR Clustered Regularly Interspaced Short Palindromic Repeats
  • Cas CRISPR Associated
  • the CRISPR/Cas system is a preferred site-specific nuclease in a method for identifying a locus or in a method for generating a library.
  • the CRISPR/Cas system targets DNA for cleavage via a short, complementary single-stranded RNA (CRISPR RNA or crRNA) adjoined to a short palindromic repeat.
  • CRISPR RNA or crRNA complementary single-stranded RNA
  • the processing of the targeting RNA is dependent on the presence of a transactivating crRNA (tracrRNA) that has sequence complementary to the palindromic repeat. Hybridization of the tracrRNA to the palindromic repeat sequence triggers processing.
  • the processed RNA activates the Cas9 domain and directs its activity to the complementary sequence within DNA.
  • the system has been simplified to direct Cas9 cleavage from a single RNA transcript and has been directed to many different sequences within the genome (Shalem et al.
  • a method for generating a library as described herein use of meganucleases, ZFNs, TALE nuclease or nucleic acid guided systems such as the CRISPR/Cas9 systems as site-specific nucleases will enable targeting of endogenous loci within the genome.
  • heterologous recognition sites i.e. recognition sequences
  • site-specific nucleases including meganucleases, ZFNs and TALE nucleases
  • Nuclease-directed targeting could be used to drive insertion of recognition sequences by homologous recombination or NHEJ using vector DNA or even double stranded
  • SUBSTITUTE SHEET (RULE 26) oligonucleotides (Orlando et al. Nucleic Acids Research 2010; 38(15): e152).
  • non-specific targeting methods could be used to introduce recognition sequences for site-specific nucleases through the use of transposon-directed integration (Cadinanos & Bradley. Nucleic Acids Research 2007; 35(12): e87).
  • Viralbased systems such as lentivirus, applied at low titre could also be used to introduce recognition sequences.
  • the site-specific nuclease may be encoded by a single gene that is introduced on one plasmid, whereas the donor DNA is present on a second plasmid.
  • combinations could be used incorporating two or more of these elements on the same plasmid and this could enhance the efficiency of targeting by reducing the number of number of plasmids to be introduced in a method for identifying a locus or a method for generating a library.
  • it may be possible to pre-integrate the nuclease(s) which could also be inducible to allow temporal control of nuclease activity as has been demonstrated for transposases (Cadinanos & Bradley. Nucleic Acids Research 2007; 35(12): e87).
  • the nuclease could be introduced as recombinant protein or protein: RNA complex (for example in the case of an RNA directed nuclease such as CRISPR:Cas9).
  • a method for generating a library involves providing a site-specific nuclease which cleaves a recognition sequence in cellular DNA.
  • the recognition sequence is in the AAVS locus, as described for example in WO2015/166272, incorporated herein by reference in its entirety.
  • the recognition sequence is in the ROSA26 locus, as described for example in Perez-Pinera et al. Nucleic Acids Research 2012; 40(8), incorporated herein by reference in its entirety.
  • Suitable recognition sequences are described in WO2023/025834, incorporated herein by reference in its entirety.
  • the recognition sequence is in a neurolysin (NLN) gene, as described for example in WO2023/025834, incorporated herein by reference in its entirety.
  • the eukaryotic cells used may contain endogenous sequences recognized by the site-specific nuclease or the recognition sequence may be engineered into the cellular DNA as earlier described herein.
  • the neurolysin gene (human sequence: Uniprot Q9BYT8, ENSEMBL gene id ENSG00000123213) encodes a member of the metallopeptidase M3 protein family that cleaves neurotensin at the Pro10-Tyr11 bond, leading to the formation of neurotensin (1-10) and neurotensin (11- 13).
  • An exemplary sequence of a neurolysin gene is represented by SEQ ID NO: 3.
  • the recognition sequence is in a nucleic acid molecule represented
  • SUBSTITUTE SHEET by a nucleotide sequence comprising, consisting essentially of, or consisting of SEQ ID NO: 1 , or a nucleotide sequence having at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with SEQ ID NO: 3.
  • the recognition sequence is in a TRAF2 and NCK interacting kinase (TNIK) gene (Uniprot Q9UKE5, ENSEMBL gene id ENSG00000154310), as described for example in WO2023/025834, incorporated herein by reference in its entirety.
  • TNIK NCK interacting kinase
  • An exemplary sequence of a TNIK gene is represented by SEQ ID NO: 4.
  • the recognition sequence is in a protein mono-ADP- ribosyltransferase 11 (PARP11) gene (Uniprot Q9NR21 , ENSEMBL gene id ENSG00000111224), as described for example in WQ2023/025834, incorporated herein by reference in its entirety.
  • PARP11 protein mono-ADP- ribosyltransferase 11
  • An exemplary sequence of a PARP11 gene is represented by SEQ ID NO: 5.
  • the recognition sequence is in a RAB40B gene (member RAS oncogene family, Uniprot Q12829, ENSEMBL gene id ENSG00000141542), as described for example in WQ2023/025834, incorporated herein by reference in its entirety.
  • An exemplary sequence of a RAB40B gene is represented by SEQ ID NO: 6.
  • the recognition sequence is in an abl interactor 2 (ABI2) gene (Uniprot Q9NYB9, ENSEMBL gene id ENSG00000138443), as described for example in WQ2023/025834, incorporated herein by reference in its entirety.
  • An exemplary sequence of an ABI2 gene is represented by SEQ ID NO: 7.
  • the recognition sequence is in a ring finger protein 19B (RNF19B) gene (Uniprot Q6ZMZ0, ENSEMBL gene id ENSG00000116514), as described for example in WQ2023/025834, incorporated herein by reference in its entirety.
  • RNF19B gene is represented by SEQ ID NO: 8.
  • the recognition sequence is in a cAMP-dependent protein kinase inhibitor alpha (PKIA) gene (Uniprot P61925, ENSEMBL gene id ENSG00000171033), as described for example in WQ2023/025834, incorporated herein by reference in its entirety.
  • PKIA protein kinase inhibitor alpha
  • An exemplary sequence of a PKIA gene is represented by SEQ ID NO: 9.
  • the recognition sequence is in a formimidoyltransferase cyclodeaminase (FTCD) gene (Uniprot 095954, ENSEMBL gene id ENSG00000160282), as described for example in WO2023/025834, incorporated herein by reference in its entirety.
  • FTCD formimidoyltransferase cyclodeaminase
  • An exemplary sequence of an FTCD gene is represented by SEQ ID NO: 10.
  • the recognition sequence is in an NLN gene, a TNIK gene or a RAB40B gene. In some embodiments, the recognition sequence is in a nucleic acid molecule represented by a nucleotide sequence comprising, consisting essentially of,
  • SUBSTITUTE SHEET (RULE 26) or consisting of SEQ ID NOs: 3-10, or a nucleotide sequence having at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with SEQ ID NO: 3-10.
  • the recognition sequence is in an intron of a gene selected from an NLN, TNIK, PARP11, RAB40B, ABI2, RNF19B, PKIA, or FTCD gene, preferably an NLN, TNIK, or RAB40B genes, as described for example in WO2023/025834, incorporated herein by reference in its entirety.
  • intron is used herein as customarily and ordinarily understood by the skilled person.
  • a recognition sequence in an intron of NLN is preferably in NLN-207 intron 1 (intron 1- 2), intron 2 (intron 2-3) or intron 6 (intron 6-7).
  • a recognition sequence in an intron of TNIK is preferably in TNIK-04 (Ensembl ID ENST00000436636.7) intron 2 (intron 2-3).
  • a recognition sequence in an intron of PARP11 is preferably in PARP11-205 (Ensembl ID ENST00000450737.2) intron 1 (intron 1-2).
  • a recognition sequence in an intron of RAB40B is preferably in RAB40B-206 (Ensembl ID ENST00000571995.6) intron 1 (intron 1-2).
  • a recognition sequence in an intron of ABI2 is preferably in ABI2-203 (Ensembl ID ENST00000261018.12) intron 1 (intron 1-2).
  • a recognition sequence in an intron of RNF19B is preferably in RNF19B-201 (Ensembl ID ENST00000235150.5) intron 1 (intron 1-2).
  • a recognition sequence in an intron of PKIA is preferably in PKIA- 202 (Ensembl ID ENST00000396418.7) intron 1 (intron 1-2).
  • a recognition sequence in an intron of FTCD is preferably in FTCDNL1-201 (Ensembl ID ENST00000416668.5) intron 3 (intron 3-4).
  • the recognition sequence is in an intron of a neurolysin gene.
  • the canonical transcript of the human neurolysin (NLN) gene is NLN-201 (Ensembl transcript ID: ENST00000380985.10) which comprises 13 exons.
  • An alternative transcript is NLN-207 (Ensembl transcript ID: ENST00000509935.2) which comprises 7 exons.
  • the recognition sequence is in NLN-201 intron 1 of a neurolysin gene (NLN-201 intron 1-2; exemplary sequence: SEQ ID NO: 11).
  • the recognition sequence is in NLN-201 intron 2 of a neurolysin gene (NLN-201 intron 2-3; exemplary sequence: SEQ ID NO: 12).
  • the recognition sequence is in NLN-201 intron 3 of a neurolysin gene (NLN-201 intron 3-4; exemplary sequence: SEQ ID NO: 13). In some embodiments, the recognition sequence is in NLN-201 intron 4 of a neurolysin gene (NLN-201 intron 4-5; exemplary sequence: SEQ ID NO: 14). In some embodiments, the recognition sequence is in NLN-201 intron 5 of a neurolysin gene (NLN-201 intron 5-6; exemplary sequence: SEQ ID NO: 15). In some embodiments, the recognition sequence is in NLN-201 intron 6 of a neurolysin gene (NLN-201 intron 6-7; exemplary sequence: SEQ ID NO: 16). In some
  • the recognition sequence is in NLN-201 intron 7 of a neurolysin gene (NLN-201 intron 7-8; exemplary sequence: SEQ ID NO: 17). In some embodiments, the recognition sequence is in NLN-201 intron 8 or NLN-207 intron 1 of a neurolysin gene (NLN-201 intron 8-9 or NLN-207 intron 1-2; exemplary sequence: SEQ ID NO: 18). In some embodiments, the recognition sequence is in NLN-201 intron 9 or NLN-207 intron 2 of a neurolysin gene (NLN-201 intron 9-10 or NLN-207 intron 2-3; exemplary sequence: SEQ ID NO: 19).
  • the recognition sequence is in NLN- 201 intron 10 or NLN-207 intron 3 of a neurolysin gene (NLN-201 intron 10-11 or NLN- 207 intron 3-4; exemplary sequence: SEQ ID NO: 20).
  • the recognition sequence is in NLN-201 intron 11 or NLN-207 intron 4 of a neurolysin gene (NLN-201 intron 11-12 or NLN-207 intron 4-5; exemplary sequence: SEQ ID NO: 21).
  • the recognition sequence is in intron 12 of a NLN-201 neurolysin gene (NLN-201 intron 12-13; exemplary sequence: SEQ ID NO: 22).
  • the recognition sequence is in intron 5 of a NLN-207 neurolysin gene (NLN-207 intron 5-6; exemplary sequence: SEQ ID NO: 23). In some embodiments, the recognition sequence is in intron 6 of a NLN-207 neurolysin gene (NLN-207 intron 6-7; exemplary sequence: SEQ ID NO: 24).
  • Preferred introns are NLN-207 introns 1 , 2, and 6 of an NLN gene.
  • the recognition sequence is in a nucleic acid molecule represented by a nucleotide sequence comprising, consisting essentially of, or consisting of SEQ ID NOs: 18, 19, 24, or a nucleotide sequence having at least 60%, 61%, 62%, 63%, 64%, 65%,
  • the recognition sequence is in an intron of a gene selected from an NLN, TNIK, PARP11 , RAB40B, ABI2, RNF19B, PKIA, or FTCD gene as described above, the recognition sequence is in an open chromatin region of the intron.
  • the recognition sequence is in an intron of a gene selected from an NLN, TNIK, PARP11 , RAB40B, ABI2, RNF19B, PKIA, or FTCD gene as described above, the recognition sequence is in an enhancer region of the intron.
  • open chromatin or “euchromatin” or “loose chromatin” refers to a structure that is permissible for transcription whereas “heterochromatin” or “tight” or “closed” chromatin is more compact and more refractory to factors that need to gain access to the DNA template.
  • a recognition sequence for the site-specific nuclease in a method as described herein may be present in genomic DNA, or episomal DNA which is stably inherited in the cells. Donor DNA may therefore be integrated at a genomic or episomal locus in the cellular DNA.
  • a donor DNA is targeted to a single site within the eukaryotic genome. Identification of a cell demonstrating a particular binding activity or cellular phenotype will allow direct isolation of the gene encoding the desired property (e.g., by PCR from mRNA or genomic DNA). This is facilitated by using a unique recognition sequence for the site-specific nuclease, occurring once in the cellular DNA. Cells used for creation of the library may thus contain a nuclease recognition sequence at a single fixed locus, i.e., one identical locus in all cells. Libraries produced from such cells will contain donor DNA integrated at the fixed locus, i.e., occurring at the same locus in cellular DNA of all clones in the library.
  • recognition sequences may occur multiple times in cellular DNA, so that the cells have more than one potential integration site for donor DNA. This would be a typical situation for diploid or polyploid cells where the recognition sequence is present at corresponding positions in a pair of chromosomes, i.e., replicate loci.
  • Libraries produced from such cells may contain donor DNA integrated at replicate fixed loci.
  • libraries produced from diploid cells may have donor DNA integrated at duplicate fixed loci and libraries produced from triploid cells may have donor DNA integrated at triplicate fixed loci.
  • Many suitable mammalian cells are diploid, and clones of mammalian cell libraries as described herein may have donor DNA integrated at duplicate fixed loci.
  • the sequence recognised by the site-specific nuclease may occur at more than one independent locus in the cellular DNA.
  • Donor DNA may therefore integrate at multiple independent loci.
  • Libraries of diploid or polyploid cells may comprise donor DNA integrated at multiple independent fixed loci and/or at replicate fixed loci.
  • each locus represents a potential integration site for a molecule of donor DNA.
  • Introduction of donor DNA into the cells may result in integration at the full number of nuclease recognition sequences present in the cell, or the donor DNA may integrate at some but not all of these potential sites.
  • the resulting library may comprise clones in which donor DNA is integrated at the first fixed locus, clones in which donor DNA is integrated at the
  • SUBSTITUTE SHEET (RULE 26) second fixed locus, and clones in which donor DNA is integrated at both the first and second fixed loci.
  • Methods of producing libraries as described herein may therefore involve site-specific nuclease cleavage of multiple fixed loci in a cell, and integration of donor DNA at the multiple fixed loci.
  • nucleic acid sequences encoding a binder (or binder subunit) will be integrated, particularly when an efficient targeting mechanisms is used, with only one nucleic acid sequence encoding a binder (or binder subunit) being specific to the target. This can be resolved during subsequent screening once nucleic acid sequences encoding a binder (or binder subunit) have been isolated.
  • a method for generating a library as described herein may comprise integrating a donor DNA.
  • Preferred donor DNA molecules are described in this section.
  • the donor DNA will usually be circularised DNA, and may be provided as a plasmid or vector. Linear DNA is another possibility. Donor DNA molecules may comprise regions that do not integrate into the cellular DNA, in addition to one or more donor DNA sequences that integrate into the cellular DNA.
  • the DNA is typically double-stranded, although single-stranded DNA may be used in some cases.
  • the donor DNA contains one or more transgenes encoding a binder, for example it may comprise a promotergene cassette.
  • double-stranded, circular plasmid DNA can be used to drive homologous recombination. This requires regions of DNA flanking the transgenes which are homologous to DNA sequence flanking the cleavage site in genomic DNA. Linearised double-stranded plasmid DNA or PCR product or synthetic genes could be used to drive both homologous recombination and NHEJ repair pathways.
  • double-stranded DNA it is possible to use single-stranded DNA to drive homologous recombination (Fujioka et al. Nucleic Acids Res 1993; 21(3): 407-412).
  • a common approach to generating single-stranded DNA is to include a single-stranded origin of replication from a filamentous bacteriophage into the plasmid.
  • Single-stranded DNA viruses such as adeno-associated virus (AAV) have been used to drive efficient homologous recombination where the efficiency has been shown to be improved by several orders of magnitude (Khan et al. Nat Prot 2011 ; 6(4): 482-501); Deyle & Russell. Current Opinion in Molecular Therapeutics 2009; 11(4): 442-447).
  • Systems such as the AAV systems could be used in conjunction with nuclease-directed cleavage in a method for identifying a locus and in a method for generating a library.
  • SUBSTITUTE SHEET (RULE 26) The benefits of both systems could be applied to in a method for identifying a locus and in a method for generating a library.
  • the packaging limit of AAV vectors is 4.7 kb but the use of nuclease digestion of target genomic DNA will reduce this allowing larger transgene constructs to be incorporated.
  • a molecule of donor DNA may encode a single binder or multiple binders.
  • multiple subunits of a binder may be encoded per molecule of donor DNA.
  • donor DNA encodes a subunit of a multimeric binder.
  • the donor DNA comprises one or more nucleic acid sequences encoding a binding domain coupled to an Fc domain.
  • T ranscription of the binder or binder subunit from the encoding donor DNA will usually be achieved by placing the sequence encoding the binder or binder subunit under control of a promoter and optionally one or more enhancer elements for transcription.
  • a promoter (and optionally other genetic control elements) may be included in the donor DNA molecule itself.
  • the sequence encoding the binder may lack a promoter on the donor DNA, and instead may be placed in operable linkage with a promoter on the cellular DNA, e.g., an endogenous promoter or a pre-integrated exogenous promoter, as a result of its insertion at the integration site created by the site-specific nuclease.
  • a promoter on the cellular DNA e.g., an endogenous promoter or a pre-integrated exogenous promoter
  • the donor DNA molecules as described herein comprise a first promoter operably linked to the first nucleic acid sequence and/or a second promoter operably linked to the second nucleic acid sequence.
  • the first and second promoter are the same. In preferred embodiments, the first and second promoter are different. In some embodiments, each of the first and second promoter may independently be a constitutive or an inducible promoter, preferable a constitutive promoter. Suitable constitutive promoters include a CM promoter, a CAG promoter and an EF1 alpha promoter, or variants thereof. Preferred promoters are a CMV and an EF1 alpha promoter. A more preferred promoter is a CMV promoter.
  • each of the first and second promoter may independently be selected from the group consisting of a CMV promoter, a CAG promoter and an EF1 alpha promoter, preferably from the group consisting of a CMV promoter and an EF1 alpha promoter.
  • the first promoter is a CMV promoter and the second promoter is an EF1 alpha promoter, or the first promoter is an EF1 alpha promoter and the second promoter is a CMV promoter. More preferably, the first promoter is a CMV promoter and the second promoter is an EF1 alpha promoter.
  • the donor DNA molecules as described herein comprise a bidirectional promoter operably linked to the first and second nucleic acid sequence.
  • a preferred bidirectional promoter is a bidirectional CMV promoter.
  • Donor DNA may further comprise one or more further coding sequences, such as genetic elements enabling selection of cells containing or expressing the donor DNA.
  • Such an element may be called a selectable marker.
  • such elements may be associated with a promoter on the donor DNA or may be placed under control of a promoter as a result of integration of the donor DNA at a fixed locus. The latter arrangement provides a convenient means of selecting specifically for those cells which have integrated the donor DNA at the desired site, since these cells should express the genetic element for selection. This may be, for example, a gene conferring resistance to a negative selection agent such as blasticidin or puromycin.
  • One or more selection steps may be applied to remove unwanted cells, such as cells that lack the donor DNA or which have not integrated the donor DNA at the correct position.
  • a membrane anchored binder could itself be used as a form of selectable marker.
  • ten cells which express the binder can be selected using secondary reagents which recognise the surface expressed Fc using methods described herein.
  • transient expression (and cell surface expression) of the binder will occur and it will be necessary to wait for transient expression to abate (to achieve targeted integration of e.g., 1- 2 antibody genes/cell).
  • a construct encoding a membrane tethering element or a membrane anchor (e.g., the Fc domain of the present example fused to the PDGF receptor transmembrane domain) could be pre-integrated before the binders sequences are introduced.
  • methods as described herein are such that the first and/or second nucleic acid sequence as described herein further encodes a membrane anchor, such as a transmembrane domain or a membrane localization signal.
  • a membrane anchor such as a transmembrane domain or a membrane localization signal.
  • a preferred transmembrane domain is the PDGF receptor transmembrane domain.
  • a preferred membrane localization signal is a GPI recognition sequence.
  • a membrane anchor as described herein is fused to the binder (subunit), more preferably to the Fc domain.
  • the first but not the second nucleic acid sequence further encodes a membrane anchor. In some embodiments, the second but not the first nucleic acid sequence further encodes a membrane anchor.
  • this membrane-tethering element lacks a promoter or is encoded within an exon which is out of frame with the preceding exon then surface expression will be compromised. Targeted integration of an incoming donor molecule can then correct this defect (e.g., by targeting a promoter or an “in-frame” exon into the intron which is upstream of the defective tethering element). If the frame “correcting exon” also encodes a binder then a fusion will be produced between the binder and the membrane tethering element resulting in surface expression of both. Thus correctly targeted integration will result inframe expression of the membrane tethering element alone or as part of a fusion with the incoming binder. Furthermore if the incoming library of binders lack a membrane tethering element and these are incorrectly integrated they will not be selected. Thus expression of the binder itself on the cell surface can be used to select the population of cells with correctly targeted integration.
  • a method for generating a library as described herein is for generating a library of eukaryotic cell clones containing DNA encoding a diverse repertoire of bispecific binders.
  • a library refers to a library of eukaryotic cell clones containing DNA encoding a diverse repertoire of binders which may be obtained via one of these methods, unless explicitly mentioned otherwise.
  • Preferred libraries and their properties are defined in this section.
  • Yeast display libraries of 10 7 -10 10 have previously been constructed and demonstrated to yield binders in the absence of immunisation or pre-selection of the population (Chao et al. Nat Protoc 2006; 1(2): 755-768; Benatuil et al. Protein Engineering, Design and Selection 2010; 23(4): 155-159; Feldhaus et al. Nat Biotechnol 2003; 21 :163-170; Zhao et al. Journal of Immunological Methods 2011 ; 363(2):221-232).
  • Many of the previously published mammalian display libraries used antibody genes derived from immunised donors or even enriched antigen-specific B lymphocytes, given the limitations of library size and variability when using cells from higher eukaryotes. Thanks to the efficiency of gene targeting in the methods described herein large, naive libraries can be constructed in higher eukaryotes such as mammalian cells, which match those described for simpler eukaryotes such as yeast.
  • the resulting recombinant cells are cultured to allow their replication, generating a clone of cells from each initially- produced recombinant cell. Each clone is thus derived from one original cell into which
  • SUBSTITUTE SHEET (RULE 26) donor DNA was integrated at an integration site created by the site-specific nuclease. Methods as described herein are associated with a high efficiency and high fidelity of donor DNA integration, and a library as described herein may contain at least 100, 10 3 , 10 4 , 10 5 , 10 6 , 10 7 , 10 8 , 10 9 or 10 1 ° clones.
  • nuclease-directed integration it is possible to target 10 % or more of transfected mammalian cells. It is also practical to grow and transform >10 1 ° cells (e.g. from 5 litres of cells growing at 2 x10 6 cells/ml). Transfection of such large numbers of cells could be done using standard methods including polyethyleneimine — mediated transfection as described herein. In addition methods are available for highly efficient electroporation of 10 1 ° cells in 5 minutes e.g. http://www.maxcyte.com. Thus using the approach of the present disclosure it is possible to create libraries in excess of 10 9 clones.
  • the population of donor DNA molecules that is used to create the library contains multiple copies of the same sequence, two or more clones may be obtained that contain DNA encoding the same binder. It can also be the case that a clone may contain donor DNA encoding more than one different binder, for example if there is more than one recognition sequence for the site-specific nuclease, as detailed elsewhere herein. Thus, the diversity of the library, in terms of the number of different binders encoded or expressed, may be different from the number of clones obtained.
  • Clones in the library preferably contain donor DNA encoding one or two members of the repertoire of binders and/or preferably express only one or two members of the repertoire of binders.
  • a limited number of different binders per cell is an advantage when it comes to identifying the clone and/or DNA encoding a particular binder identified when screening the library against a given target. This is simplest when clones encode a single member of the repertoire of binders. However it is also straightforward to identify the relevant encoding DNA for a desired binder if a clone selected from a library encodes a small number of different binders, for example a clone may encode two members of the repertoire of binders.
  • clones encoding one or two binders are particularly convenient to generate by selecting a recognition sequence for the site-specific nuclease that occurs once per chromosomal copy in a diploid genome, as diploid cells contain duplicate fixed loci, one on each chromosomal copy, and the donor DNA may integrate at one or both fixed loci.
  • clones of the library may each express only one or two members of the repertoire of binders.
  • Binders displayed on the surface of cells of the library may be identical to (having the same amino acid sequence as) other binders displayed on the same cell.
  • the library may consist of clones of cells which each display a single member of the repertoire of binders, or of clones displaying a plurality of members of the repertoire of binders per
  • a library may comprise some clones that display a single member of the repertoire of binders, and some clones that display a plurality of members (e.g., two) of the repertoire of binders.
  • a library as described herein may comprise clones encoding more than one member of the repertoire of binders, wherein the donor DNA is integrated at duplicate fixed loci or multiple independent fixed loci.
  • a molecule of donor DNA will encode a single binder.
  • the binder may be multimeric so that a molecule of donor DNA includes multiple genes or open reading frames corresponding to the various subunits of the multimeric binder.
  • a library as described herein may encode at least 100, 10 3 , 10 4 , 10 5 or 10 6 , 10 7 , 10 8 , 10 9 or 10 1 ° different binders.
  • the binders are multimeric, diversity may be provided by one or more subunits of the binder.
  • Multimeric binders may combine one or more variable subunits with one or more constant subunits, where the constant subunits are the same (or of more limited diversity) across all clones of the library.
  • combinatorial diversity is possible where a first repertoire of binder subunits may pair with any of a second repertoire of binder subunits.
  • the libraries preferably have any one or more of the following features:
  • a library may encode and/or express at least 100, 10 3 , 10 4 , 10 5 , 10 6 , 10 7 , 10 8 or 10 9 different binders.
  • a library may consist of clones containing donor DNA integrated at a fixed locus, or at a limited number of fixed loci in the cellular DNA. Each clone in the library therefore contains donor DNA at the fixed locus or at least one of the fixed loci. Preferably clones contain donor DNA integrated at one or two fixed loci in the cellular DNA. As explained elsewhere herein, the integration site is at a recognition sequence for a site-specific nuclease. Integration of donor DNA to produce recombinant DNA is described in detail elsewhere herein and can generate different results depending on the number of integration sites. Where there is a single potential integration site in cells used to generate the library, the library will be a library of clones containing donor DNA integrated at the single fixed locus. All clones of the library therefore contain the binder genes at the same position in the cellular DNA. Alternatively where
  • the library may be a library of clones containing donor DNA integrated at multiple and/or different fixed loci.
  • each clone of a library contains donor DNA integrated at a first and/or a second fixed locus.
  • a library may comprise clones in which donor DNA is integrated at a first fixed locus, clones in which donor DNA is integrated at a second fixed locus, and clones in which donor DNA is integrated at both the first and second fixed loci.
  • there are only one or two fixed loci in the clones in a library although it is possible to integrate donor DNA at multiple loci if desired for particular applications.
  • each clone may contain donor DNA integrated at any one or more of several fixed loci, e.g., three, four, five or six fixed loci.
  • clones of the library may contain DNA encoding a first binder subunit integrated at a first fixed locus and DNA encoding a second binder subunit integrated at a second fixed locus, wherein the clones express multimeric binders comprising the first and second subunits.
  • Binders displayed on the surface of cells of the library may be identical to (having the same amino acid sequence as) other binders displayed on the same cell.
  • the library may consist of clones of cells which each display a single member of the repertoire of binders, or of clones displaying a plurality of members of the repertoire of binders per cell.
  • a library may comprise some clones that display a single member of the repertoire of binders, and some clones that display a plurality of members (e.g., two) of the repertoire of binders.
  • clones of a library express one or two members of the repertoire of binders.
  • a library of eukaryotic cell clones according to the present disclosure may express a repertoire of at least 10 3 , 10 4 , 10 5 10 6 , 10 7 , 10 8 or 10 9 different binders, each cell containing donor DNA integrated at a fixed locus in the cellular DNA.
  • the donor DNA encodes the binder and may further comprise a genetic element for selection of cells into which the donor DNA is integrated at the fixed locus.
  • Cells of the library may contain DNA encoding an exogenous site-specific nuclease.
  • SUBSTITUTE SHEET (RULE 26)
  • the present disclosure extends to the library either in pure form, as a population of library clones in the absence of other eukaryotic cells, or mixed with other eukaryotic cells.
  • Other cells may be eukaryotic cells of the same type (e.g., the same cell line) or different cells. Further advantages may be obtained by combining two or more libraries as described herein, or combining a library as described herein with a second library or second population of cells, either to facilitate or broaden screening or for other uses as are described herein or which will be apparent to the skilled person.
  • a library as described herein, one or more clones obtained from the library, or host cells into which DNA encoding a binder from the library has been introduced, may be provided in a cell culture medium.
  • the cells may be cultured and then concentrated to form a cell pellet for convenient transport or storage.
  • the library may be in a container such as a cell culture flask containing cells of the library suspended in a culture medium, or a container comprising a pellet or concentrated suspension of eukaryotic cells comprising the library.
  • the library may constitute at least 75 %, 80 %, 85 % or 90 % of the eukaryotic cells in the container.
  • the fixed locus where the donor DNA is integrated for the libraries as described herein corresponds with the location of the recognition sequence of methods for generating a library as described herein.
  • all preferences for the location of the recognition sequences as described herein are also applicable to the fixed locus of the library as described herein.
  • a library built in the context of this disclosure may be cultured to express the bispecific binders in either soluble secreted form or in transmembrane form, preferably in transmembrane form. It is said that the expressed bispecific binders are “displayed” if they are retained on the surface of the cells which encode them.
  • terms like “binder display”, “display on/at the surface”, “display on the cell”, “display of the binder” and the like may be used interchangeably.
  • a library may also be called a display or a display library.
  • a library wherein the expressed bispecific binders are displayed is to provide a repertoire of bispecific binders for screening against a target of interest.
  • Bispecific binders may comprise or be linked to a membrane anchor, such as a transmembrane domain, for extracellular display of the binder at the cell surface. This may involve direct fusion of the binder, i.e. one or both of its subunits, to a membrane localisation signal such as a GPI recognition sequence or to a transmembrane domain such as the transmembrane domain of the PDGF receptor, as described elweshere
  • a membrane tethered Fc can "sample" secreted binder molecules being expressed in the same cell resulting in display of a monomeric fraction of the binder molecules being expressed while the remainder is secreted in a bivalent form (US 8,551 ,715).
  • An alternative is to use a tethered IgG binding domain such as protein A.
  • the binder is directly tethered to the cell surface it is possible to generate a soluble product.
  • the gene encoding the selected binder can be recovered and cloned into an expression vector lacking the membrane anchored sequence.
  • an expression construction can be used in which the transmembrane domain is encoded within an exon flanked by recombination sites, e.g., ROX recognition
  • SUBSTITUTE SHEET (RULE 26) sites for Ore recombinase (Anastassiadis et al. Disease Models & Mechanisms 2009; 2(9-10):508-515).
  • the exon encoding the transmembrane domain can be removed by transfection with a gene encoding Dre recombinase to switch expression to a secreted form.
  • one or more library clones may be selected and used to produce a further, second generation library.
  • the library may be cultured to express the bispecific binders, and one or more clones expressing bispecific binders of interest may be recovered, for example by selecting bispecific binders against a target, optionally two targets, via a method for identifying a bispecific binder to a target as described herein.
  • These clones may subsequently be used to generate a derivative library containing DNA encoding a second repertoire of bispecific binders, preferably via a method for producing a library as described herein.
  • DNA of the one or more recovered clones is mutated to provide the second repertoire of bispecific binders.
  • Mutations may be addition, substitution or deletion of one or more nucleotides.
  • the binder is a polypeptide
  • mutation will be to change the sequence of the encoded binder by addition, substitution or deletion of one or more amino acids.
  • Mutation may be focussed on one or more regions, such as one or more CDRs of an antibody molecule, providing a repertoire of bispecific binders of a common structural class which differ in one or more regions of diversity, as described elsewhere herein.
  • Generating the derivative library may comprise isolating DNA from the one or more recovered clones, introducing mutation into the DNA to provide a derivative population of donor DNA molecules encoding a second repertoire of bispecific binders, and introducing the derivative population of donor DNA molecules into cells to create a derivative library of cells containing DNA encoding the second repertoire of bispecific binders.
  • Isolation of the DNA may involve obtaining and/or identifying the DNA from the clone. Such methods may encompass amplifying the DNA encoding a bispecific binder from a recovered clone, e.g., by PGR and introducing mutations. DNA may be sequenced and mutated DNA synthesised.
  • SUBSTITUTE SHEET (RULE 26) Mutation may alternatively be introduced into the DNA in the one or more recovered clones by inducing mutation of the DNA within the clones.
  • the derivative library may thus be created from one or more clones without requiring isolation of the DNA, e.g., through endogenous mutation in avian DT40 cells.
  • Antibody display lends itself especially well to the creation of derivative libraries. Once antibody genes are isolated, it is possible to use a variety of mutagenesis approaches (e.g., error prone PCR, oligonucleotide-directed mutagenesis, chain shuffling) to create display libraries of related clones from which improved variants can be selected. For example, with chain-shuffling the DNA encoding the population of selected VH clone, oligoclonal mix or population can be sub-cloned into a vector encoding a suitable antibody format and encoding a suitably formatted repertoire of VL chains (Dyson et al. Anal Biochem 2011 ; 417(1): 25-35).
  • mutagenesis approaches e.g., error prone PCR, oligonucleotide-directed mutagenesis, chain shuffling
  • the VH clone, oligomix or population could be introduced into a population of eukaryotic cells which encode and express a population of appropriately formatted light chain partners (e.g., a VL-CL chain for association with an IgG or Fab formatted heavy chain).
  • the VH population could arise from any of the sources discussed above including B cells of immunised animals or scFv genes from selected phage populations.
  • cloning of selected VHs into a repertoire of light chains could combine chain shuffling and re-formatting (e.g., into IgG format) in one step.
  • a particular advantage of display on eukaryotic cells is the ability to control the stringency of the selection/screening step. By reducing antigen concentration, cells expressing the highest affinity binders can be distinguished from lower affinity clones within the population.
  • the visualisation and quantification of the affinity maturation process using flow cytometry is a major benefit of eukaryotic display as it gives an early indication of percentage positives in naive library and allows a direct comparison between the affinity of the selected clones and the parental population during sorting.
  • the affinity of individual clones can be determined by pre-incubating with a range of antigen concentrations and analysis in flow cytometry or with a homogenous Time Resolved Fluorescence (TRF) assay or using surface plasmon resonance (SPR) (Biacore).
  • TRF Time Resolved Fluorescence
  • SPR surface plasmon resonance
  • the eukaryotic cell library may be used in a method of screening for a bispecific binder that recognises a target of interest, optionally two targets of interest. Accordingly, an an aspect, there is provided a use of a library as described herein as a display library for selecting bispecific binders to a target of interest, optionally to two targets of interest.
  • Such a method may comprise: providing a library via the method for producing a library as described herein, or providing a library as described herein, culturing cells of the library to express the bispecific binders, exposing the bispecific binders to the target, optionally the two targets, allowing recognition of the target, optionally of the two targets, by one or more binders of interest, if present, and detecting whether the target, optionally the two targets, is recognised by a binder of interest.
  • a method according to this aspect may be called a method for identifying a binder to a target in the context of this application.
  • the selection of binder or the screening for a binder also refer to such a method.
  • Methods for identifying a bispecific binder to a target may be carried out using a range of target molecule classes, e.g., protein, nucleic acid, carbohydrate, lipid, small molecules.
  • the target may be provided in soluble form.
  • the target may be labelled to facilitate detection, e.g., it may carry a fluorescent label or it may be biotinylated.
  • Cells expressing a target-specific binder may be isolated using a directly or indirectly labelled target molecule, where the binder captures the labelled molecule. For example, cells that are bound, via the bindertarget interaction, to a fluorescently labelled target can be detected and sorted by flow cytometry or FACS to isolate the desired cells.
  • Target molecules which are directly fluorescently labelled or are labelled with molecules which can be detected with secondary reagents e.g., biotinylated target can be added to cells and binding to the cell surface can be detected with fluorescently labelled streptavidin such as streptavidin-phycoerythrin.
  • secondary reagents e.g., biotinylated target can be added to cells and binding to the cell surface can be detected with fluorescently labelled streptavidin such as streptavidin-phycoerythrin.
  • streptavidin such as streptavidin-phycoerythrin.
  • a further possibility is to immobilise the target molecule or secondary reagents which bind to the target on a solid surface, such as magnetic beads or agarose beads, to allow enrichment of cells which bind the target.
  • cells that bind, via the binder: target interaction, to a biotinylated target can be isolated on a substrate coated with streptavidin, e.g., strept
  • SUBSTITUTE SHEET (RULE 26) streptavidin-coated magnetic beads could be used to capture cells which have bound to biotinylated antigen. Selection with magnetic beads could be used as the only selection method or this could be done in conjunction with flow cytometry where better resolution can be achieved, e.g., differentiating between a clone with higher expression levels and one with a higher affinity (Feldhaus et al. Nat Biotechnol 2003;21(2):163-170; Zhao et al. Journal of Immunological Methods 2011 ; 363(2): 221-232).
  • Targets could be tagged through chemical modification (fluorescein, biotin) or by genetic fusion (e.g. protein fused to an epitope tag such as a FLAG tag or another protein domain or a whole protein).
  • the tag could be nucleic acid (e.g., DNA, RNA or non-biological nucleic acids) where the tag is part fused to target nucleic acid or could be chemically attached to another type of molecule such as a protein. This could be through chemical conjugation or through enzymatic attachment (Gu et al. Nat Biotechnol 2013; 30(2): 144-152). Nucleic acid could be also fused to a target through a translational process such as ribosome display.
  • nucleic acid e.g., DNA, RNA or non-biological nucleic acids
  • the “tag” may be another modification occurring within the cell (e.g., glycosylation, phosphorylation, ubiqitinylation, alkylation, PASylation, SUMO-lation and others described at the Post-translational Database (db-PTM) at https://awi.cuhk.edu.cn/dbPTM, see Li et al. Nucleic Acids Research 2022; 50(D1): D471-479) which can be detected via secondary reagents. This would yield binders which bind an unknown target protein on the basis of a particular modification.
  • db-PTM Post-translational Database
  • Targets could be detected using existing binders which bind to that target molecule, e.g., target specific antibodies.
  • Use of existing binders for detection will have the added advantage of identifying binders within the library of binders which recognise an epitope distinct from the binder used for detection. In this way pairs of binders could be identified for use in applications such as sandwich ELISA. Where possible a purified target molecule would be preferred.
  • the target may be displayed on the surface of a population of target cells and the binders are displayed on the surface of the library cells, the method comprising exposing the binders to the target by bringing the library cells into contact with the target cells.
  • the target molecule could also be unpurified recombinant or unpurified native targets provided a detection molecule is available to identify cell binding (as described above).
  • SUBSTITUTE SHEET (RULE 26)
  • binding of target molecules to the cell expressing the bispecific binder could be detected indirectly through the association of target molecule to another molecule which is being detected, e.g., a cell lysate containing a tagged molecule could be incubated with a library of binders to identify binders not only to the tagged molecule but also binders to its associated partner proteins. This would result in a panel of antibodies to these partners which could be used to detect or identify the partner (e.g., using mass spectrometry). Cellular fractionation could be used to enrich targets from particular sub-cellular locations.
  • differential biotinylation of surface or cytoplasmic fractions could be used in conjunction with streptavidin detection reagents for eukaryotic display (Cho & Shusta. Protein Eng Des Sei 2010; 23(7): 567-577).
  • the use of detergent solubilised target preparations is a particularly useful approach for intact membrane proteins such as GPCRs and ion channels which are otherwise difficult to prepare.
  • the presence of detergents may have a detrimental effect on the eukaryotic cells displaying the binders requiring recovery of binder genes without additional growth of the selected cells.
  • cells of a clone containing DNA encoding the binder of interest may be recovered.
  • DNA encoding the binder may then be isolated (e.g., identified or amplified) from the recovered clone, thereby obtaining DNA encoding a binder that recognises the target.
  • the DNA encoding a binder that recognises the target may be sequenced.
  • binders and targets are detailed elsewhere herein.
  • a classic example is a library of bispecific antibody molecules, which may be screened for binding to a target antigen of interest, optionally two target antigens of interest.
  • the binder is able to modify cell signaling and/or cellular behavior as a result of the action of the bispecific binder on the target(s).
  • the bispecific binder is a bispecific antibody.
  • the eukaryotic cell library may be used in a method of screening for a cell of a desired phenotype, wherein the phenotype results from expression of a bispecific binder by the cell. Accordingly, an an aspect, there is provided a use of a library as decribed herein for screening for cells displaying a desired cellular phenotype, wherein the phenotype results from expression of a bispecific binder by a cell.
  • Such a method may comprise:
  • SUBSTITUTE SHEET (RULE 26) providing a library via the method for producing a library as described herein, or providing a library as described herein; culturing cells of the library to express the bispecific binders; and detecting whether the desired phenotype is exhibited.
  • a method according to this aspect may be called a method for screening for a cell of a desired phenotype in the context of this application.
  • Bispecific antibodies which modify cell signalling by binding to ligands or receptors have a proven track record in drug development and the demand for such therapeutic antibodies continues to grow.
  • Such antibodies and other classes of functional bispecific binders also have potential in controlling cell behaviour in vivo and in vitro.
  • the ability to control and direct cellular behaviour however relies on the availability of natural ligands which control specific signalling pathways.
  • natural ligands such as those controlling stem cell differentiation (e.g., members of FGF, TGF-beta, Wnt and Notch super-families) often exhibit promiscuous interactions and have limited availability due to their poor expression/stability profiles. Due to their specificity, bispecific antibodies have great potential in controlling cellular behaviour.
  • a population of antibody genes may be introduced into reporter cells to produce a library by methods described herein, and clones within the population with an antibody-directed
  • SUBSTITUTE SHEET alteration in phenotype (e.g., altered gene expression or survival) can be identified.
  • phenotypic-directed selection to work there is a requirement to retain a linkage between the antibody gene present within the expressing cell (genotype) and the consequence of antibody expression (phenotype). This has been achieved previously either through tethering the antibody to the cell surface (Zhang et al. Chemistry & Biology 2013;20(5), 734 — 741) as described for antibody display or through the use of semi- solid medium to retain secreted antibodies in the vicinity of producing cells (Melidoni et al. Proceedings of the National Academy of Sciences 2013; 110(44), 17802 — 1780). Alternatively antibodies and other binders can be retained inside the cell (Xie et al. Chemistry & Biology 2014; 2(2), 274 — 283).
  • Binders retained on the cell surface or in the surrounding medium can interact with an endogenous or exogenous receptor on the cell surface causing activation of the receptor. This in turn can cause a change in expression of a reporter gene or a change in the phenotype of the cell.
  • the antibody can block the receptor or ligand to reduce receptor activation.
  • the gene encoding the binder which causes the modified cellular behaviour can then be recovered for production or further engineering.
  • it is possible to introduce a “naive” antibody population which has not been pre-selected to a particular target (Yea et al. PNAS 2013; 110:14966-14971).
  • the cellular reporting system is used to identify members of the population with altered behaviour.
  • the “functional selection” approach could be used on other applications involving libraries in eukaryotic cells, particularly higher eukaryotes such as mammalian cells.
  • the antibody could be fused to a signalling domain such that binding to target causes activation of the receptor.
  • Kawahara et al. have constructed chimeric receptors where an extra-cellular scFv targeting fluorescein was fused to a spacer domain (the D2 domain of the Epo receptor) and various intracellular cytokine receptor domain including the thrombopoeitin (Tpo) receptor, erythropoietin (Epo) receptor, gp130, IL-2 receptor and the EGF receptor (Kawahara et al.
  • SUBSTITUTE SHEET demonstrate antigen mediated chemoattraction of BaF3 cells [110], The approach was extended beyond stable culture cells to primary cells exemplified by the survival and growth of Tpo-responsive haematopoeitic stem cells (Kawahara et al. Cytokine 2011 ; 55(3): 402-408) or IL2 dependant primary T cells where normal stimulation by Tpo and IL-2 respectively was replaced by fluorescein directed stimulation of scFv chimaeric receptors.
  • a system based on chimaeric antibody-receptor chimaeras can be used to drive target dependent gene expression or phenotypic changes in primary or stable reporter cells. This capacity could be used to identify fused binders which drive a signalling response or binders which inhibit the response.
  • a binder i.c. an antibody molecule
  • a target may also be adapted and performed with libraries of other types of binders.
  • Protein fragment complementation represents an alternative system for studying and for selecting proteimprotein interactions in mammalian cells (Kerppola. Chemical Society Reviews 2009; 38(10): 2876-2886, Michnick et al. Nature Reviews Drug Discovery 2007; 6(7): 569/582). This involves restoring function of split reporter proteins through proteimprotein interactions.
  • Reporter proteins which have been used include ubiquitin, DNAE intein, beta-galactosidase, dihydrofolate reductase, GFP, firefly luciferase, beta-lactamase, TEV protease.
  • a recent example of this approach is the mammalian membrane 2 hybrid (MaMTH) approach where association of a bait proteimsplit ubiquitimtranscription factor fusion with a partner proteimsplit ubiquitin restores ubiquitin recognition and liberates the transcription factor to effect reporter gene expression (Petschnigg et al. Nat Methods 2014; 11(5):585-92). Again binders which interfere with or enhance this interaction could be identified through perturbed signalling.
  • MaMTH mammalian membrane 2 hybrid
  • cells of a clone that exhibits the desired phenotype may then be recovered.
  • DNA encoding the binder may then be isolated (e.g., identified or amplified) from the recovered clone, thereby obtaining DNA encoding a bispecific binder which produces the desired phenotype when expressed in the cell.
  • the DNA encoding a binder that recognises the target may be sequenced.
  • SUBSTITUTE SHEET (RULE 26)
  • cells of a clone that exhibits the desired phenotype may then be recovered.
  • DNA encoding the bispecific binder is then isolated from the recovered clone, providing DNA encoding a bispecific binder which produces the desired phenotype when expressed in the cell.
  • the DNA encoding a bispecific binder which produces the desired phenotype may be sequenced.
  • a common next step will be to isolate (e.g., identify or amplify) the DNA encoding the binder.
  • it may be desired to modify the nucleic acid encoding the binder for example to restructure the binder and/or to insert the encoding sequence into a different vector.
  • a preferred method for identifying a binder to a target comprises isolating the DNA encoding the binder recognizing the target. More preferred methods are described below.
  • a preferred method for identifying a binder to a target comprises isolating DNA encoding the antibody molecule from cells of a clone, amplifying DNA encoding at least one antibody variable region, preferably both the VH and VL domain, and inserting DNA into a vector to provide a vector encoding the antibody molecule.
  • a method for producing a library of eukaryotic cell clones containing DNA encoding a diverse repertoire of bispecific binders comprising: providing eukaryotic cells; providing a plurality of donor DNA molecules, each donor DNA molecule comprising a first nucleic acid sequence encoding a first binding domain coupled to a first Fc domain; and a second nucleic acid sequence encoding a second binding domain coupled to a second Fc domain; introducing the donor DNA into the cells; and culturing the recombinant cells to produce clones, thereby providing a library of eukaryotic cell clones containing DNA encoding the repertoire of bispecific binders.
  • SUBSTITUTE SHEET (RULE 26) 2.
  • a method for producing a library of eukaryotic cell clones containing DNA encoding a diverse repertoire of multimeric, e.g. dimeric, bispecific binders comprising: providing eukaryotic cells containing DNA encoding a first subunit of the bispecific binders, the DNA comprising a first nucleic acid sequence encoding a first binding domain coupled to a first Fc domain; providing a plurality of donor DNA molecules encoding a second subunit of the bispecific binders, each donor DNA molecule comprising a second nucleic acid sequence encoding a second binding domain coupled to a second Fc domain; introducing the donor DNA into the cells, thereby creating recombinant cells which contain donor DNA integrated in the cellular DNA; and culturing the recombinant cells to produce clones containing DNA encoding the first and second subunits, thereby providing a library of eukaryotic cell clones containing DNA
  • a method for producing a library of eukaryotic cell clones containing DNA encoding a diverse repertoire of multimeric, e.g. dimeric, bispecific binders comprising: providing eukaryotic cells; providing a plurality of first donor DNA molecules encoding a first subunit of the bispecific binders, each donor DNA molecule comprising a first nucleic acid sequence encoding a first binding domain coupled to a first Fc domain; introducing the first donor DNA into the cells to create a first set of recombinant cells containing the first donor DNA integrated in the cellular DNA; culturing the first set of recombinant cells to produce a first set of clones containing DNA encoding the first subunit; providing a plurality of second donor DNA molecules encoding a second subunit of the bispecific binders, each donor DNA molecule comprising a second nucleic acid sequence encoding a second binding domain coupled to a second Fc domain; introducing the second donor DNA into cells of the
  • SUBSTITUTE SHEET (RULE 26) 4.
  • a method for producing a library of eukaryotic cell clones containing DNA encoding a diverse repertoire of multimeric, e.g. dimeric, bispecific binders comprising: providing eukaryotic cells; providing a plurality of first donor DNA molecules encoding a first subunit of the bispecific binders, each donor DNA molecule comprising a first nucleic acid sequence encoding a first binding domain coupled to a first Fc domain; providing a plurality of second donor DNA molecules encoding a second subunit of the bispecific binders, each donor DNA molecule comprising a second nucleic acid sequence encoding a second binding domain coupled to a second Fc domain; introducing the first and second donor DNA into the cells to create recombinant cells containing the first and second donor DNA integrated in the cellular DNA; and culturing the recombinant cells to produce clones, thereby providing a library of eukaryotic cell clones
  • one or more of the step(s) of introducing the donor DNA into the cells comprises providing a sitespecific nuclease within the cells, wherein the nuclease cleaves a recognition sequence in cellular DNA to create an integration site at which the donor DNA becomes integrated into the cellular DNA, integration occurring through DNA repair mechanisms endogenous to the cells, thereby creating recombinant cells containing donor DNA integrated in the cellular DNA.
  • SUBSTITUTE SHEET (RULE 26) 9. A method according to any one of paragraphs 6-8, wherein the recognition sequence is in an intron of a gene.
  • bispecific binders are bispecific antibody molecules.
  • bispecific binders are multimeric, for example dimeric, comprising at least a first and a second subunit.
  • first and/or second binding domain comprises a single antibody variable domain, preferably a variable domain derived from a heavy-chain antibody such as a VHH or a VNAR, and/or wherein the first and/or second binding domain comprises two antibody variable domains, preferably a single-chain variable fragment (scFv).
  • a single antibody variable domain preferably a variable domain derived from a heavy-chain antibody such as a VHH or a VNAR
  • two antibody variable domains preferably a single-chain variable fragment (scFv).
  • the first binding domain comprises a single antibody variable domain, preferably a variable domain derived from a heavy-chain antibody such as a VHH or a NAR, more preferably a VHH.
  • the second binding domain comprises two antibody variable domains, preferably a single-chain variable fragment (scFv).
  • scFv single-chain variable fragment
  • the donor DNA molecules comprise a first promoter operably linked to the first nucleic acid sequence and/or wherein the donor DNA molecules comprise a second promoter operably linked to the second nucleic acid sequence.
  • first and/or second nucleic acid sequence encodes a membrane anchor, such as a transmembrane domain or a membrane localization signal.
  • the repertoire of bispecific binders is a plurality of polypeptides which share a common structure and have one or more regions of amino acid sequence diversity.
  • the bispecific binder further comprises one or more additional subunits, which may be introduced on the same donor DNA as the first or second subunit or which may be integrated at separate sites in the cellular DNA.
  • the cells are mammalian cells, preferably wherein the cells are human cells.
  • cells are HEK293 cells, Chinese hamster ovary (CHO) cells, T lymphocyte lineage cells or B lymphocyte lineage cells or any of the cell lines listed in the “Cancer Cell Line Encyclopedia” or “COSMIC catalogue of somatic mutations in cancer”.
  • cells are primary B cells, a B cell line, a pre-B cell line or a pro-B cell line.
  • nuclease is a zinc finger nuclease (ZFN).
  • the nuclease is a TALE nuclease.
  • nuclease is a nucleic acid guided nuclease.
  • the donor DNA comprises a genetic element for selection of cells into which the donor DNA is integrated.
  • the donor DNA comprises a sequence encoding the bispecific binder or a subunit thereof operably linked to a promoter.
  • eukaryotic cells are diploid and contain a recognition sequence for the site-specific nuclease at duplicate fixed loci in the cellular DNA.
  • each clone contains integrated donor DNA encoding a single member of the repertoire of bispecific binders.
  • a method further comprising: culturing the library to express the bispecific binders, recovering one or more clones expressing a bispecific binder of interest, and generating a derivative library from the one or more recovered clones, wherein the derivative library contains DNA encoding a second repertoire of bispecific binders.
  • a method according to paragraph 55 wherein generating the derivative library comprises isolating donor DNA from the one or more recovered clones, introducing mutation into the DNA to provide a derivative population of donor DNA molecules encoding a second repertoire of bispecific binders, and introducing the derivative population of donor DNA molecules into cells to create a derivative library of cells containing DNA encoding the second repertoire of bispecific binders.
  • a method according to paragraph 55, wherein generating the derivative library comprises introducing mutation into the donor DNA in the one or more recovered clones by inducing mutation of the DNA within the clones.
  • SUBSTITUTE SHEET (RULE 26) 58 A method of producing a diverse repertoire of bispecific binders, comprising producing a library by a method according to any one of the preceding paragraphs and culturing the library cells to express the bispecific binders.
  • a method of screening for a cell of a desired phenotype, wherein the phenotype results from expression of a bispecific binder by the cell comprising
  • phenotype is expression of a reporter gene in a cell that expresses the binder.
  • a method according to paragraph 60 or paragraph 61 further comprising recovering cells of a clone that expresses a bispecific binder that produces the desired phenotype.
  • a method according to paragraph 62 further comprising isolating DNA encoding the bispecific binder from the recovered clone, thereby obtaining DNA encoding a bispecific binder which produces the desired phenotype.
  • a method of screening for a bispecific binder that recognises a target of interest comprising:
  • SUBSTITUTE SHEET (RULE 26) 66.
  • a method according to paragraph 64 wherein the target is displayed on the surface of a population of target cells and the bispecific binders are displayed on the surface of the library cells, the method comprising exposing the bispecific binders to the target by bringing the library cells into contact with the target cells.
  • bispecific binders are bispecific antibody molecules and the target is an antigen.
  • a method according to any one of paragraphs 64 to 67 further comprising detecting target recognition by a bispecific binder of interest, and recovering cells of a clone containing DNA encoding the bispecific binder of interest.
  • a method according to paragraph 68 further comprising isolating DNA encoding the bispecific binder from the recovered clone, thereby obtaining DNA encoding a bispecific binder that recognises the target.
  • a method according to paragraph 63, 69, 70 or 71 further comprising introducing the DNA into a host cell.
  • SUBSTITUTE SHEET (RULE 26) 75 A library according to paragraph 59, 73 or 74 wherein the bispecific binders are antibody molecules.
  • a container containing eukaryotic cells comprising a library according to any one of paragraphs 59 or 73 to 75.
  • promoter or “regulatory sequence” refers to a nucleic acid fragment that functions to control the transcription of one or more coding sequences, and is located upstream with respect to the direction of transcription of the transcription initiation site of the coding sequence, and is structurally identified by the presence of a
  • SUBSTITUTE SHEET (RULE 26) binding site for DNA-dependent RNA polymerase, transcription initiation sites and any other DNA sequences, including, but not limited to transcription factor binding sites, repressor and activator protein binding sites, and any other sequences of nucleotides known to one of skill in the art to act directly or indirectly to regulate the amount of transcription from the promoter.
  • a "constitutive" promoter is a promoter that is active in most tissues under most physiological and developmental conditions.
  • An “inducible” and/or “repressible” promoter is a promoter that is physiologically or developmentally regulated to be induced and/or repressed, e.g. by the application of a chemical inducer or repressing signal.
  • operably linked refers to a linkage of polynucleotide elements in a functional relationship.
  • a nucleic acid is “operably linked” when it is placed into a functional relationship with another nucleic acid sequence.
  • a transcription regulatory sequence such as s a promoter is operably linked to a coding sequence if it affects the transcription of the coding sequence.
  • Operably linked means that the DNA sequences being linked are typically contiguous and, where necessary to join two protein encoding regions, contiguous and in reading frame.
  • protein or “polypeptide” are used interchangeably and refer to molecules consisting of a chain of amino acids, without reference to a specific mode of action, size, 3-dimensional structure or origin.
  • each nucleic acid molecule or protein fragment or polypeptide or peptide or derived peptide or construct as identified herein by a given sequence identity number is not limited to this specific sequence as disclosed.
  • Each coding sequence as identified herein encodes a given protein fragment or polypeptide or peptide or derived peptide or construct or is itself a protein fragment or polypeptide or construct or peptide or derived peptide.
  • SUBSTITUTE SHEET (RULE 26) iii. a nucleotide sequence that encodes an amino acid sequence that has at least 60% amino acid identity or similarity with an amino acid sequence encoded by a nucleotide sequence SEQ ID NO: X.
  • Another preferred level of sequence identity or similarity is 65%. Another preferred level of sequence identity or similarity is 70%. Another preferred level of sequence identity or similarity is 75%. Another preferred level of sequence identity or similarity is 80%. Another preferred level of sequence identity or similarity is 85%. Another preferred level of sequence identity or similarity is 90%. Another preferred level of sequence identity or similarity is 95%. Another preferred level of sequence identity or similarity is 97%. Another preferred level of sequence identity or similarity is 99%. Another preferred level of sequence identity or similarity is 99.5%.
  • Another preferred level of sequence identity or similarity is 65%.
  • Another preferred level of sequence identity or similarity is 70%.
  • Another preferred level of sequence identity or similarity is 75%.
  • Another preferred level of sequence identity or similarity is 80%.
  • Another preferred level of sequence identity or similarity is 85%.
  • Another preferred level of sequence identity or similarity is 90%.
  • Another preferred level of sequence identity or similarity is 95%.
  • Another preferred level of sequence identity or similarity is 97%.
  • Another preferred level of sequence identity or similarity is 99%.
  • Another preferred level of sequence identity or similarity is 99.5%.
  • Each nucleotide sequence or amino acid sequence described herein by virtue of its identity or similarity percentage with a given nucleotide sequence or amino acid sequence respectively has in a further preferred embodiment an identity or a similarity of at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.
  • Each non-coding nucleotide sequence i.e. of a promoter or of another regulatory region
  • a nucleotide sequence comprising a nucleotide sequence
  • SUBSTITUTE SHEET (RULE 26) that has at least 60% sequence identity or similarity with a specific nucleotide sequence SEQ ID NO (take SEQ ID NO: A as example).
  • a preferred nucleotide sequence has at least 60%, at least 61%, at least 62%, at least 63%, at least 64%, at least 65%, at least 66%, at least 67%, at least 68%, at least 69%, at least 70%, at least 71%, at least 72%, at least 73%, at least 74%, at least 75%, at least 76%, at least 77%, at least 78%, at least 79%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%
  • such non-coding nucleotide sequence such as a promoter exhibits or exerts at least an activity of such a non-coding nucleotide sequence such as an activity of a promoter as known to a person of skill in the art.
  • sequence identity is described herein as a relationship between two or more amino acid (polypeptide or protein) sequences or two or more nucleic acid (polynucleotide) sequences, as determined by comparing the sequences.
  • sequence identity is calculated based on the full length of two given SEQ ID NO’s or on a part thereof, preferably based on the full length. Part thereof preferably means at least 50%, 60%, 70%, 80%, 90%, or 100% of both SEQ ID NO’s.
  • identity also refers to the degree of sequence relatedness between amino acid or nucleic acid sequences, as the case may be, as determined by the match between strings of such sequences. "Similarity" between two amino acid sequences is determined by comparing the amino acid sequence and its conserved amino acid substitutes of one polypeptide to the sequence of a second polypeptide.
  • Sequence identity and “sequence similarity” can be determined by alignment of two peptide or two nucleotide sequences using global or local alignment algorithms, depending on the length of the two sequences. Sequences of similar lengths are preferably aligned using a global alignment algorithm (e.g. Needleman-Wunsch) which aligns the sequences optimally over the entire length, while sequences of substantially different lengths are preferably aligned using a local alignment algorithm (e.g. Smith- Waterman). Sequences may then be referred to as "substantially identical” or
  • SUBSTITUTE SHEET (RULE 26) “essentially similar” when they (when optimally aligned by for example the program EMBOSS needle or EMBOSS water using default parameters) share at least a certain minimal percentage of sequence identity (as described below).
  • a global alignment is suitably used to determine sequence identity when the two sequences have similar lengths.
  • local alignments such as those using the Smith-Waterman algorithm, are preferred.
  • EMBOSS needle uses the Needleman-Wunsch global alignment algorithm to align two sequences over their entire length (full length), maximizing the number of matches and minimizing the number of gaps.
  • EMBOSS water uses the Smith-Waterman local alignment algorithm.
  • the default scoring matrix used is DNAfull and for proteins the default scoring matrix is Blosum62 (Henikoff & Henikoff, 1992, PNAS 89, 915-919, incorporated herein by reference).
  • nucleic acid and protein sequences of some embodiments of the present disclosure can further be used as a “query sequence” to perform a search against public databases to, for example, identify other family members or related sequences.
  • search can be performed using the BLASTn and BLASTx programs (version 2.0) of Altschul, et al. (1990) J. Mol. Biol. 215:403-10, incorporated herein by reference.
  • Gapped BLAST can be utilized as described in Altschul et al., (1997) Nucleic Acids Res. 25(17): 3389-3402, incorporated herein by reference.
  • the default parameters of the respective programs e.g., BLASTx and BLASTn
  • conservative amino acid substitutions refer to the interchangeability of residues having
  • a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains
  • SUBSTITUTE SHEET (RULE 26) is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulphur- containing side chains is cysteine and methionine.
  • Preferred conservative amino acids substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysinearginine, alanine-valine, and asparagine-glutamine.
  • Substitutional variants of the amino acid sequence disclosed herein are those in which at least one residue in the disclosed sequences has been removed and a different residue inserted in its place.
  • the amino acid change is conservative.
  • Preferred conservative substitutions for each of the naturally occurring amino acids are as follows: Ala to Ser; Arg to Lys; Asn to Gin or His; Asp to Glu; Cys to Ser or Ala; Gin to Asn; Glu to Asp; Gly to Pro; His to Asn or Gin; lie to Leu or Vai; Leu to lie or Vai; Lys to Arg; Gin or Glu; Met to Leu or He; Phe to Met, Leu or Tyr; Ser to Thr; Thr to Ser; Trp to Tyr; Tyr to Trp or Phe; and, Vai to lie or Leu.
  • the verb “to consist” may be replaced by “to consist essentially of” meaning that a composition as described herein may comprise additional component(s) than the ones specifically identified, said additional component(s) not altering the unique characteristic of this disclosure.
  • the verb “to consist” may be replaced by “to consist essentially of” meaning that a method as described herein may comprise additional step(s) than the ones specifically identified, said additional step(s) not altering the unique characteristic of this disclosure.
  • At least a particular value means that particular value or more.
  • “at least 2” is understood to be the same as “2 or more” i.e., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, ..., etc.
  • the word “about” or “approximately” when used in association with a numerical value preferably means that the value may be the given value (of 10) more or less 5%, preferably more or less 1% of the value.
  • the term “and/or” indicates that one or more of the stated cases may occur, alone or in combination with at least one of the stated cases, up to with all of the stated cases.
  • FIG. 1 Schematic representations of bispecific antibody expression cassettes plNT177, a dual CM promoter expression cassette for surface expression.
  • plNT178 a dual promoter expression cassette for surface expression. Expression of each antibody is provided by different promoter, namely CMV and pEF.
  • SUBSTITUTE SHEET (RULE 26) plNT179, a dual CMV promoter surface expression cassette similar to plNT177, but where scFv is attached to the “hole” part and VHH is attached to the “knob” part of a bispecific molecule.
  • FIG. 1 Non-reduced Western blot of bispecific antibodies described in Table 1. Arrows indicate positions of heterodimers. Western blots were probed with anti-Fc (a) and anti-Myc (b) detection antibodies.
  • FIG. 1 Expression of monospecific (A, B) and bispecific (C, D) antibodies on cell surface.
  • Cells were stained with either with human anti-Fc-phycoerythrin antibody (A, C) or anti-Myc-FITC antibody (B, D).
  • FIG. 4 Expression of monospecific (B, C) and bispecific (D) antibodies on cell surface. Cells were stained with anti-Flag-FITC antibody, non-transfected HEK293F cell are shown for comparison (A).
  • FIG. 1 Antibody binding of antigen on cell surface.
  • Cells expressing monospecific (B, C) or bispecific (D) antibodies were incubated with 1 nM biotinylated antigen 1 and streptavidin-APC.
  • Non-transfected HEK293F cell are shown for comparison (A).
  • FIG. Antibody binding of antigen on cell surface.
  • Cells expressing monospecific (B, C) or bispecific (D) antibodies were incubated with 59 nM antigen 2- FITC labelled antigen.
  • Non-transfected HEK293F cell are shown for comparison (A).
  • Figure 7 Dual antigen binding to bispecific antibodies expressed on cell surface.
  • Cells were transfected with expressing cassettes 3-6 listed in the Table Z where antibody genes are expressed either under dual CMV promoter (A, B) or CMV-pEF promoter (C, D).
  • Antibodies were incubated with 59 nM antigen 2-FITC labelled antigen, and 1 nM biotinylated antigen 1. Streptavidin-APC was used for detection in latter case.
  • Figure 8 Titration binding of antigen 1 in the presence or absence of saturating concentration of unlabeled antigen 2.
  • Cells were transfected with plNT178-4B12 VHH- ”hole” (Flag): 3G01 scFv-”knob”(Myc) construct, and stained with increasing concentration of antigen 1 detected with streptavidin-APC. Saturating concentration of antigen 2 (180 nM) was applied prior to antigen 1 staining.
  • FIG. 9 FACS selection of binders from bispecific mammalian display libraries.
  • Mammalian display libraries containing VHH repertoires directly cloned from immunized llamas (A) or following 2 rounds of phage display selection on antigen 1 (B) were stained with biotinylated antigen 1 antigen (APC secondary detection) in the presence of saturating antigen 2-FITC for enrichment of bispecific molecules capable of simultaneous binding to both antigens. Boxes indicate sort gates.
  • SUBSTITUTE SHEET (RULE 26) expressed as individual clones and bispecific antibodies were tested for antigen 1 binding by DELFIA TRF assay.
  • Signal against antigen 1-biotin immobilized on streptavidin shows as grey bars and control values on stredtavidin only antigen (i.e. no antigen 1) are overlayed as black bars.
  • FIG. 11 Schematic overview of bispecific vector knob into hole technology and of the vector region between the homology arms.
  • antigenic targets in the below examples are not disclosed and are denoted as “antigen 1" and “antigen 2”. Both antigen 1 and antigen 2 are representative transmembrane proteins expressed by certain immune cells.
  • binders e.g., antibody, protein, or peptide
  • Antibodies represent the most commonly used class of binders, and they can be formatted for expression in different forms.
  • VHH and scFv variable binding entities of different classes
  • a VHH denoted as 4B12 is an antibody that specifically binds to antigen 1
  • scFvs denoted as 4F07 and 3G01 are antibodies (fragments) that specifically bind to antigen 2.
  • the first plasmid was created to combine the promoter of cytomegalovirus (CM promoter) that was used to drive expression of VHH antibody and constant regions of heavy chain containing “hole” mutations (T366S:L368A:Y407V; see also P Carter, Bispecific human IgG by design. J Immunol Methods 248, 7-15 (2001)), and for expression of scFv followed by constant regions of heavy chain
  • CM promoter cytomegalovirus
  • SUBSTITUTE SHEET (RULE 26) containing a “knob” mutation (T366W; see also P Carter, Bispecific human IgG by design. J Immunol Methods 248, 7-15 (2001)).
  • the latter cistron contains PDGF receptor transmembrane domain in order to provide membrane anchoring.
  • VHH secretion is directed by a BM40 leader sequence [Holden, P., Keene, D. R., Lunstrum, G. P., Bachinger, H. P., & Horton, W. A. (2005). Secretion of cartilage oligomeric matrix protein is affected by the signal peptide. J Biol Chem, 280(17), 17172-17179], This is followed by ApaLI and BstEII restriction sites which allow in-frame cloning of any antibody. Secretion of the scFv is directed by a leader split by an intron originating from a mouse VH gene. The coding sequence of the signal peptide is followed by Ncol and Notl sites allowing in frame cloning of genes encoding the antibody with binding properties that are different from the first antibody.
  • Elongation factor-1 alpha protein is ubiquitously and abundantly expressed in most eukaryotic cells and its promoter (pEF promoter, also called the EF1 alpha promoter) is commonly used for driving transgene expression [Kim, D. W., Uetsuki, T., Kaziro, Y., Yamaguchi, N., & Sugano, S. (1990).
  • pEF promoter also called the EF1 alpha promoter
  • pEF promoter also called the EF1 alpha promoter
  • Example 2 Western blot of bispecific antibodies expressed in mammalian cells Western blot was performed to confirm bispecific antibody formation in cells transfected with the bispecific antibody display vectors.
  • HEK293 cells were transfected with vectors listed in Table 1 , using nuclease (TALEN) directed integration using homology arms targeting the NLN locus (see also Example 3 of WO2023/025834 and Examples 6 and 7 of WO2015/166272, both incorporated herein by reference.
  • Protein fractions were prepared using RIPA buffer (ThermoFisherScientific, Cat. N 89901) as recommended by the manufacturer. Protein samples comprising antibodies were resolved by gel electrophoresis in non-reducing conditions and then transferred to PVDF membrane. The separated proteins on the membrane were then probed with anti-Fc and anti-Myc antibodies conjugated to horseradish peroxidase (HRP), and detected with HRP enhanced chemiluminescence substrate.
  • HRP horseradish peroxidase
  • Dual antigen binding to bispecific antibodies expressed under either dual CMV or CMV- pEF promoters is shown in Figure 7. Briefly, cells expressing 4B12 VHH and 4F07 scFv or 4B12 VHH and 3G01 scFv were stained with both antigens 1 and 2 essentially as described above. Dual staining shows detection of the bispecific antibodies irrespectively of the promoters used for expression of separate arms. Best antigen binding and bispecific display for 4B12:4F07 is observed with the pCMV pEF promoter combination.
  • SUBSTITUTE SHEET (RULE 26) Cell lines stained with both antigens revealed presence of double-positive population. However, concentrations of the antigens were not saturating therefore it is unclear whether the bispecific antibodies bind one antigen at a time or both simultaneously. To this end, antigen 1 titration was performed in the presence and absence of saturating unlabeled antigen 2 according to the protocol outlined above. For a bispecific antibody capable of simultaneous antigen binding, similar results would be anticipated between the two conditions, whereas an antibody not capable of simultaneous binding may exhibit reduced antigen 1 binding VHH arm due to high scFv arm occupancy with antigen 2. Data presented on Figure 8 shows little if any competition for antigen 1 binding demonstrating simultaneously occupancy of both binding arms with respective antigens.
  • anti-antigen 1 VHH repertoires directly from immunized llamas, or following 2 rounds of phage display were cloned into the plNT178 vector system by restriction cloning using ApaL1 and BstEII.
  • Mammalian display libraries of bispecific molecules were generated from the resulting plNT178 plasmid libraries as described in detail previously (WO2015/166272, WO2023/025834, Parthiban et al. MAbs 2019; 11(5);884-898; Dyson et al. MAbs 2020; 12(1):1829335).
  • HEK293 cells were transfected unsing the MaxCyte electroporation system, and passaged with antibiotic selection (7.5 pg/ml blasticidin). Magnetic-activated cell sorting (MACS) for antibody expression was performed at least 6 days post-transfection to generate integrated mammalian display libraries of 10 5 - 10 7 clones. FACS selections from these bispecific mammalian display libraries are shown in Figure 9 (FACS of the
  • SUBSTITUTE SHEET (RULE 26) library directly cloned from immunized llamas is presented in panel A and the phage display enriched input library is shown in panel B).
  • Cell staining was performed as described previously and above (Parthiban et al. MAbs 2019; WO2015/166272). Cells were sorted for antibody binding to biotinylated antigen 1 (allophycocyanin (APC) secondary detection) in the presence of saturating antigen 2-FITC (sort gates represented as boxes in Figure 9) for enrichment of bispecific molecules capable of simultaneous binding to both antigens.
  • APC allophycocyanin
  • antigen 2 binding was retained as a fixed modality in the bispecific constructs (y-axis) and antigen 1 binding (x-axis) is enriched in the phage display input relative to the directly cloned immune library.
  • Low frequency VHH antigen 1 binders that are compatible with the bispecific format and antigen 2 occupancy in the scFv-Fc arm are clearly detectable in the llama immune repertoire.
  • Enriched bispecific antibody clones were isolated and screened for binding to antigen 1 using a DELFIA TRF assay ( Figure 10).
  • DELFIA® dissociation-enhanced lanthanide fluorescence immunoassay
  • TRF time-resolved fluorescence
  • Perkin Elmer Perkin Elmer

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne des procédés de production d'une bibliothèque de clones de cellules eucaryotes contenant de l'ADN codant pour un répertoire divers de liants bispécifiques, en particulier pour des liants bispécifiques comprenant un premier domaine de liaison couplé à un premier domaine Fc et un second domaine de liaison couplé à un second domaine Fc.
PCT/EP2024/065476 2023-06-06 2024-06-05 Préparation de bibliothèques de liants bispécifiques exprimés dans des cellules eucaryotes Ceased WO2024251820A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP24731906.4A EP4724577A1 (fr) 2023-06-06 2024-06-05 Préparation de bibliothèques de liants bispécifiques exprimés dans des cellules eucaryotes
AU2024284377A AU2024284377A1 (en) 2023-06-06 2024-06-05 Preparation of libraries of bispecific binders expressed in eukaryotic cells
CN202480045689.1A CN121729490A (zh) 2023-06-06 2024-06-05 真核细胞中表达的双特异性结合物文库的制备

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23177536 2023-06-06
EP23177536.2 2023-06-06

Publications (1)

Publication Number Publication Date
WO2024251820A1 true WO2024251820A1 (fr) 2024-12-12

Family

ID=86760642

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2024/065476 Ceased WO2024251820A1 (fr) 2023-06-06 2024-06-05 Préparation de bibliothèques de liants bispécifiques exprimés dans des cellules eucaryotes

Country Status (4)

Country Link
EP (1) EP4724577A1 (fr)
CN (1) CN121729490A (fr)
AU (1) AU2024284377A1 (fr)
WO (1) WO2024251820A1 (fr)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034784A1 (fr) 1998-12-10 2000-06-15 Phylos, Inc. Echaffaudages de proteines pour des mimes d'anticorps et autres proteines de liaison
US20120277120A1 (en) 2011-04-27 2012-11-01 Amyris, Inc. Methods for genomic modification
US8551715B2 (en) 2010-02-12 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for identifying and isolating cells expressing a polypeptide
WO2015166272A2 (fr) 2014-05-02 2015-11-05 Iontas Limited Préparation de banques de variants de proténes s'exprimant dans des cellules eucaryotes et leur utilisation en vue de la sélection de molécules de liaison
US9834615B2 (en) * 2010-08-16 2017-12-05 Novimmune Sa Methods for the generation of multispecific and multivalent antibodies
KR20220069046A (ko) * 2019-09-23 2022-05-26 트위스트 바이오사이언스 코포레이션 단일 도메인 항체에 대한 변이체 핵산 라이브러리
WO2023025834A1 (fr) 2021-08-25 2023-03-02 Iontas Limited Préparation de banques de variants protéiques exprimés dans des cellules eucaryotes
US20230102101A1 (en) * 2020-03-05 2023-03-30 Merck Sharp & Dohme Llc Human-like heavy chain antibody variable domain (vhh) display libraries

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034784A1 (fr) 1998-12-10 2000-06-15 Phylos, Inc. Echaffaudages de proteines pour des mimes d'anticorps et autres proteines de liaison
US8551715B2 (en) 2010-02-12 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for identifying and isolating cells expressing a polypeptide
US9834615B2 (en) * 2010-08-16 2017-12-05 Novimmune Sa Methods for the generation of multispecific and multivalent antibodies
US20120277120A1 (en) 2011-04-27 2012-11-01 Amyris, Inc. Methods for genomic modification
WO2015166272A2 (fr) 2014-05-02 2015-11-05 Iontas Limited Préparation de banques de variants de proténes s'exprimant dans des cellules eucaryotes et leur utilisation en vue de la sélection de molécules de liaison
US20200165595A1 (en) * 2014-05-02 2020-05-28 Iontas Limited Preparation of libraries of protein variants expressed in eukaryotic cells and use for selecting binding molecules
KR20220069046A (ko) * 2019-09-23 2022-05-26 트위스트 바이오사이언스 코포레이션 단일 도메인 항체에 대한 변이체 핵산 라이브러리
US20230102101A1 (en) * 2020-03-05 2023-03-30 Merck Sharp & Dohme Llc Human-like heavy chain antibody variable domain (vhh) display libraries
WO2023025834A1 (fr) 2021-08-25 2023-03-02 Iontas Limited Préparation de banques de variants protéiques exprimés dans des cellules eucaryotes

Non-Patent Citations (83)

* Cited by examiner, † Cited by third party
Title
"Bioinformatics: Sequence and Genome Analysis", 2004, COLD SPRING HARBOR LABORATORY PRESS
"Proteomics and transcriptomics", 2018, SPRINGER INTERNATIONAL PUBLISHING, article "Bioinformatics and the Cell: Modern Computational Approaches in Genomics"
"Uniprot", Database accession no. 095954
ADACHI ET AL., DNA AND CELL BIOLOGY, vol. 25, no. 1, 2006, pages 19 - 24
ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 10
ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, no. 17, 1997, pages 3389 - 3402
ANASTASSIADIS ET AL., DISEASE MODELS & MECHANISMS, vol. 2, no. 9-10, 2009, pages 508 - 515
BARRETINA ET AL., NATURE, vol. 483, no. 7391, 2012, pages 603 - 607
BENATUIL ET AL., PROTEIN ENGINEERING, DESIGN AND SELECTION, vol. 23, no. 4, 2010, pages 155 - 159
BEURDELEY ET AL., NATURE COMMUNICATIONS, vol. 4, 2013, pages 1762
BIFFI ET AL., NATURE CHEMISTRY, vol. 5, no. 3, 2013, pages 182 - 186
BOGDANOVE ET AL., SCIENCE, vol. 333, no. 6051, 2011, pages 1843 - 1846
BOISSEL ET AL., NUCLEIC ACIDS RESEARCH, vol. 42, no. 4, 2013, pages 2591 - 2601
BOUBLIK ET AL., NATURE BIOTECH, vol. 13, no. 10, 1995, pages 1079 - 1084
BREOUS-NYSTROM ET AL., METHODS, vol. 65, no. 1, 2014, pages 57 - 67
BRINKMANNKONTERMANN, MABS, vol. 9, no. 2, 2017, pages 182 - 212
CADINANOSBRADLEY, NUCLEIC ACIDS RESEARCH, vol. 35, no. 12, 2007, pages e87
CARTER PAUL: "Bispecific human IgG by design", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 248, no. 1-2, 1 January 2001 (2001-01-01), pages 7 - 15, XP002974199, ISSN: 0022-1759, DOI: 10.1016/S0022-1759(00)00339-2 *
CHAO ET AL., NAT PROTOC, vol. 1, no. 2, 2006, pages 755 - 768
CHEN ET AL., ADV DRUG DELIV REV, vol. 65, no. 10, 2013, pages 1357 - 1369
CHICHILI ET AL., PROTEIN SCI., vol. 22, no. 2, 2013, pages 153 - 67
CHOSHUSTA, PROTEIN ENG DES SEL, vol. 23, no. 7, 2010, pages 567 - 577
DAVUSMAIZELS, PLOS ONE, vol. 6, no. 9, 2011, pages e23981
DEYLERUSSELL, CURRENT OPINION IN MOLECULAR THERAPEUTICS, vol. 11, no. 4, 2009, pages 442 - 447
DOYON ET AL., NAT METHODS, vol. 8, no. 1, 2011, pages 74 - 79
DYSON ET AL., ANAL BIOCHEM, vol. 417, no. 1, 2011, pages 25 - 35
DYSON ET AL., MABS, vol. 12, no. 1, 2020, pages 1829335
EPINAT ET AL., TOPICS IN CURRENT GENETICS, vol. 23, 2013, pages 147 - 185
FELDHAUS ET AL., NAT BIOTECHNOL, vol. 21, no. 2, 2003, pages 163 - 170
FORBES ET AL., NUCLEIC ACIDS RESEARCH, vol. 39, no. 3, 2011, pages D945 - 50
FUJIOKA ET AL., NUCLEIC ACIDS RES, vol. 21, no. 3, 1993, pages 1081 - 1085
GAO ET AL., PNAS, vol. 106, no. 9, 2009, pages 3071 - 3076
GEBAUERSKERRA, CURR OPIN CHEM BIOL, vol. 13, no. 3, 2009, pages 245 - 255
GREGORY L. MOORE ET AL: "A robust heterodimeric Fc platform engineered for efficient development of bispecific antibodies of multiple formats", METHODS, vol. 154, 1 February 2019 (2019-02-01), NL, pages 38 - 50, XP055625796, ISSN: 1046-2023, DOI: 10.1016/j.ymeth.2018.10.006 *
GRONWALD ET AL., PROC NATL ACAD SCI USA, vol. 85, no. 10, 1988, pages 3435 - 9
GU ET AL., NAT BIOTECHNOL, vol. 30, no. 2, 2013, pages 144 - 152
HAANMAGGOS, BIOCENTURY, vol. 12, no. 5, 2004, pages A1 - A6
HENIKOFFHENIKOFF, PNAS, vol. 89, 1992, pages 915 - 919
HOLDEN, P.KEENE, D. R.LUNSTRUM, G. PBACHINGER, H. PHORTON, W. A: "Secretion of cartilage oligomeric matrix protein is affected by the signal peptide", J BIOL CHEM, vol. 280, no. 17, 2005, pages 17172 - 17179, XP055728479, DOI: 10.1074/jbc.M411716200
JASIN, TRENDS IN GENETICS, vol. 12, no. 6, 1996, pages 224 - 228
KANAYAMA ET AL., BIOCHEM BIOPHYS RES COMMUN, vol. 327, no. 1, 2005, pages 70 - 75
KAWAHARA ET AL., BIOCHEM BIOPHYS RES COMMUN, vol. 315, no. 1, 2004, pages 132 - 138
KAWAHARA ET AL., CYTOKINE, vol. 55, no. 3, 2011, pages 402 - 408
KERPPOLA., CHEMICAL SOCIETY REVIEWS, vol. 38, no. 10, 2009, pages 2876 - 2886
KHAN ET AL., NAT PROT, vol. 6, no. 4, 2011, pages 482 - 501
KIM, D. W.UETSUKI, T.KAZIRO, YYAMAGUCHI, N.SUGANO, S: "Use of the human elongation factor 1 alpha promoter as a versatile and efficient expression system", GENE, vol. 91, no. 2, 1990, pages 217 - 223
KOIDE ET AL., JOURNAL OF MOLECULAR BIOLOGY, vol. 284, 1998, pages 1141 - 1151
KUMAR ET AL., METHODS, vol. 56, no. 3, 2012, pages 366 - 374
LETOURNEUR, FMALISSEN, B, EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 19, no. 12, 1989, pages 2269 - 2274
LI ET AL., NUCLEIC ACIDS RESEARCH, vol. 50, no. 1, 2022, pages D471 - 479
LIU HONGYAN ET AL: "Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds", vol. 8, 1 January 2017 (2017-01-01), pages 1 - 15, XP093037588, Retrieved from the Internet <URL:http://sites.utoronto.ca/sidhulab/pdf/Liu_2017_free.pdf> [retrieved on 20231017], DOI: 10.3389/fimmu.2017.00038 *
MARKS ET AL., J MOL BIOL, vol. 222, no. 3, 1991, pages 581 - 597
MELIDONI ET AL., PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 110, no. 44, 2013, pages 17802 - 1780
MICHNICK ET AL., NATURE REVIEWS DRUG DISCOVERY, vol. 6, no. 7, 2007, pages 569 - 582
MINISTRO ET AL.: "Therapeutic Antibody Engineering and Selection Strategies", ADV BIOCHEM ENG BIOTECHNOL., vol. 171, 2020, pages 55 - 86
MOEHLE ET AL., PNAS, vol. 104, no. 9, 2007, pages 3055 - 3060
MOTTERSHEAD ET AL., BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 275, 2000, pages 84 - 90
NYGREN ET AL., CURRENT OPINION IN STRUCTURAL BIOLOGY, vol. 7, 1997, pages 463 - 469
OKER-BLOM ET AL., BRIEFINGS IN FUNCTIONAL GENOMICS AND PROTEOMICS, vol. 2, no. 3, 2003, pages 244 - 253
ORLANDO ET AL., NUCLEIC ACIDS RESEARCH, vol. 38, no. 15, 2010, pages e152
P CARTER: "Bispecific human IgG by design", J IMMUNOL METHODS, vol. 248, 2001, pages 7 - 15, XP002974199, DOI: 10.1016/S0022-1759(00)00339-2
PALACIOSSTEINMETZ., CELL, vol. 41, no. 3, 1985, pages 727 - 734
PARTHIBAN ET AL., MABS, vol. 11, no. 5, 2019, pages 884 - 898
PARTHIBAN KOTHAI ET AL: "A comprehensive search of functional sequence space using large mammalian display libraries created by gene editing", vol. 11, no. 5, 4 July 2019 (2019-07-04), US, pages 884 - 898, XP055888174, ISSN: 1942-0862, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6601556/pdf/kmab-11-05-1618673.pdf> DOI: 10.1080/19420862.2019.1618673 *
PEREZ-PINERA ET AL., NUCLEIC ACIDS RESEARCH, vol. 40, no. 8, 2012, pages 3741 - 3752
PETSCHNIGG ET AL., NAT METHODS, vol. 11, no. 5, 2014, pages 585 - 92
PORTEUSBALTIMORE, SCIENCE, vol. 300, no. 5620, 2003, pages 763
REYON ET AL., NATURE BIOTECHNOLOGY, vol. 30, no. 5, 2012, pages 460 - 465
ROUET ET AL., MOLECULAR AND CELLULAR BIOLOGY, vol. 14, no. 12, 1994, pages 8096 - 8106
SAFDARI ET AL.: "Antibody humanization methods - a review and update", BIOTECHNOL GENET ENG REV, vol. 29, 2013, pages 175 - 86, XP055250530, DOI: 10.1080/02648725.2013.801235
SAMPSONWEISS, BIOESSAYS: NEWS AND REVIEWS IN MOLECULAR, CELLULAR AND DEVELOPMENTAL BIOLOGY, vol. 36, no. 1, 2014, pages 34 - 38
SHALEM ET AL., SCIENCE, vol. 343, no. 6166, 2014, pages 80 - 84
SILVA ET AL., CURRENT GENE THERAPY, vol. 11, no. 1, 2011, pages 11 - 27
SKERRA, CURR OPIN BIOTECHNOL, vol. 18, no. 4, 2007, pages 295 - 304
SOGO ET AL., CYTOKINE, vol. 46, no. 1, 2009, pages 127 - 139
SZCZEPEK ET AL., NATURE BIOTECHNOLOGY, vol. 25, no. 7, 2007, pages 786 - 793
UEDA ET AL., J IMMUNOL METHODS, vol. 241, no. 1-2, 2000, pages 159 - 170
UMOV ET AL., NATURE, vol. 435, no. 7042, 2005, pages 646 - 651
XIE ET AL., CHEMISTRY & BIOLOGY, vol. 2, no. 2, 2014, pages 274 - 283
YEA ET AL., PNAS, vol. 110, 2013, pages 14966 - 14971
ZHANG ET AL., CHEMISTRY & BIOLOGY, vol. 20, no. 5, 2013, pages 734 - 741
ZHANG ET AL., PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 109, no. 39, 2012, pages 15728 - 15733
ZHAO ET AL., JOURNAL OF IMMUNOLOGICAL METHODS, vol. 363, no. 2, 2011, pages 221 - 232

Also Published As

Publication number Publication date
AU2024284377A1 (en) 2025-12-04
AU2024284377A9 (en) 2026-01-08
EP4724577A1 (fr) 2026-04-15
CN121729490A (zh) 2026-03-24

Similar Documents

Publication Publication Date Title
US20240294899A1 (en) Preparation of libraries of protein variants expressed in eukaryotic cells and use for selecting binding molecules
EP3720959B1 (fr) Sélection pour l&#39;aptitude au développement de médicaments polypeptidiques dans des systèmes d&#39;affichage de cellules eucaryotes
WO2022126113A1 (fr) Anticorps à chaîne lourde uniquement
JP2022537203A (ja) Ｃｒｅ ｍＲＮＡを使用した標的指向性組込みによるタンパク質発現細胞の作製のための方法
US20250129362A1 (en) Preparation of libraries of protein variants expressed in eukaryotic cells
EP4724577A1 (fr) Préparation de bibliothèques de liants bispécifiques exprimés dans des cellules eucaryotes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24731906

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: AU2024284377

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2025570626

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2025570626

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2024284377

Country of ref document: AU

Date of ref document: 20240605

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112025026672

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 2024731906

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2024731906

Country of ref document: EP

Effective date: 20260107

ENP Entry into the national phase

Ref document number: 2024731906

Country of ref document: EP

Effective date: 20260107

ENP Entry into the national phase

Ref document number: 2024731906

Country of ref document: EP

Effective date: 20260107

ENP Entry into the national phase

Ref document number: 2024731906

Country of ref document: EP

Effective date: 20260107

WWP Wipo information: published in national office

Ref document number: 2024731906

Country of ref document: EP